<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">103725</article-id><article-id pub-id-type="doi">10.7554/eLife.103725</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.103725.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Decoding the biogenesis of HIV-induced CPSF6 puncta and their fusion with nuclear speckles</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tomasini</surname><given-names>Chiara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cuche</surname><given-names>Celine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ay</surname><given-names>Selen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Collard</surname><given-names>Maxence</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Rashid</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bhattacharjee</surname><given-names>Shaoni</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tello-Rubio</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Buchrieser</surname><given-names>Julian</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Luchsinger</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bertelli</surname><given-names>Cinzia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Uversky</surname><given-names>Vladimir</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Diaz-Griffero</surname><given-names>Felipe</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7021-6152</contrib-id><email>felipe.diaz-griffero@einsteinmed.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Di Nunzio</surname><given-names>Francesca</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2879-3164</contrib-id><email>dinunzio@pasteur.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f82e368</institution-id><institution>Institut Pasteur, Advanced Molecular Virology Unit, Department of Virology, Université Paris Cité</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05cf8a891</institution-id><institution>Albert Einstein College of Medicine, Department of Immunology and Microbiology</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f82e368</institution-id><institution>Institut Pasteur, Virus and Immunity Unit, Department of Virology, Université Paris Cité</institution></institution-wrap><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032db5x82</institution-id><institution>Department of Molecular Medicine and USF Health Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida</institution></institution-wrap><addr-line><named-content content-type="city">Tampa</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Comas-Garcia</surname><given-names>Mauricio</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000917t60</institution-id><institution>Universidad Autónoma de San Luis Potosí</institution></institution-wrap><country>Mexico</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05byvp690</institution-id><institution>The University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>06</day><month>01</month><year>2026</year></pub-date><volume>13</volume><elocation-id>RP103725</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-10-06"><day>06</day><month>10</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-10-09"><day>09</day><month>10</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.10.06.616889"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-12-27"><day>27</day><month>12</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103725.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-10-16"><day>16</day><month>10</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103725.2"/></event></pub-history><permissions><copyright-statement>© 2024, Tomasini, Cuche et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Tomasini, Cuche et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-103725-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-103725-figures-v1.pdf"/><abstract><p>Viruses rely on host cellular machinery for replication. After entering the nucleus, the HIV genome accumulates in nuclear niches where it undergoes reverse transcription and integrates into neighbouring chromatin, promoting high transcription rates and new virus progeny. Despite antiretroviral treatment, viral genomes can persist in these nuclear niches and reactivate upon treatment interruption, raising the possibility that they could play a role in the establishment of viral reservoirs. The post-nuclear entry dynamics of HIV remain unclear, and understanding these steps is critical for revealing how viral reservoirs are established. In this study, we elucidate the formation of HIV-induced CPSF6 puncta and the domains of CPSF6 essential for this process. We also explore the roles of nuclear speckle (NS) scaffold factors, SON and SRRM2, in the biogenesis of these puncta. Through genetic manipulation and depletion experiments, we demonstrate the key role of the intrinsically disordered region of SRRM2 in enlarging NSs in the presence of the HIV capsid. We identify the FG domain of CPSF6 as essential for both puncta formation and binding to the viral core, which serves as the scaffold for CPSF6 puncta. While the low-complexity regions modulate CPSF6 binding to the viral capsid, they do not contribute to puncta formation, nor do the disordered mixed charge domains of CPSF6. Interestingly, the FG peptide facilitates viral replication. These results demonstrate how HIV evolved to hijack host nuclear factors, enabling its persistence in the host. Of note, this study provides new insights into the underlying interactions between host factors and viral components, advancing our understanding of HIV nuclear dynamics and offering potential therapeutic targets for preventing viral persistence.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>HIV</kwd><kwd>nucleus</kwd><kwd>post-nuclear entry</kwd><kwd>condensates</kwd><kwd>nuclear speckles</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kv58h76</institution-id><institution>Agence Nationale de Recherches sur le Sida et les Hépatites Virales</institution></institution-wrap></funding-source><award-id>ECTZ192036</award-id><principal-award-recipient><name><surname>Di Nunzio</surname><given-names>Francesca</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kv58h76</institution-id><institution>Agence Nationale de Recherches sur le Sida et les Hépatites Virales</institution></institution-wrap></funding-source><award-id>ECTZ137593</award-id><principal-award-recipient><name><surname>Di Nunzio</surname><given-names>Francesca</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rbzpz17</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Di Nunzio</surname><given-names>Francesca</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kv58h76</institution-id><institution>Agence Nationale de Recherches sur le Sida et les Hépatites Virales</institution></institution-wrap></funding-source><award-id>ECTZ204694</award-id><principal-award-recipient><name><surname>Ay</surname><given-names>Selen</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kv58h76</institution-id><institution>Agence Nationale de Recherches sur le Sida et les Hépatites Virales</institution></institution-wrap></funding-source><award-id>ECTZ290008</award-id><principal-award-recipient><name><surname>Tomasini</surname><given-names>Chiara</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI087390</award-id><principal-award-recipient><name><surname>Diaz-Griffero</surname><given-names>Felipe</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AI150455</award-id><principal-award-recipient><name><surname>Diaz-Griffero</surname><given-names>Felipe</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>HIV hijacks SRRM2 to enlarge nuclear speckles, stabilizing CPSF6 puncta and promoting efficient viral replication.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Since the discovery of HIV (<xref ref-type="bibr" rid="bib4">Barré-Sinoussi et al., 1983</xref>), the initial stages of the viral life cycle, such as the reverse transcription (the conversion of the viral RNA in DNA) and the uncoating (loss of the capsid), have been understood to mainly occur within the host cytoplasm. Only the pre-integration complex, carrying the fully reverse-transcribed viral DNA, was believed to enter the nucleus for integration into the host chromatin (<xref ref-type="bibr" rid="bib59">Suzuki and Craigie, 2007</xref>). Recent studies highlighted that the viral genome is transported in the nucleus via a shuttle that shields it from the hostile cellular environment (<xref ref-type="bibr" rid="bib50">Rasaiyaah et al., 2013</xref>). This shuttle is constituted by the viral capsid (<xref ref-type="bibr" rid="bib7">Blanco-Rodriguez and Di Nunzio, 2021</xref>; <xref ref-type="bibr" rid="bib6">Blanco-Rodriguez et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Selyutina et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Yamashita and Emerman, 2004</xref>; <xref ref-type="bibr" rid="bib67">Zila et al., 2021</xref>), which comprises 250 hexamers (depending on the size and shape of the capsid) and 12 pentamers (<xref ref-type="bibr" rid="bib47">Pornillos et al., 2009</xref>). Within the structure of the capsid, hydrophobic pockets exist between hexamers, which serve as targets for various nucleoporins, especially the ones carrying FG repeats, facilitating the translocation of the capsid through the nuclear pore complex (NPC) (<xref ref-type="bibr" rid="bib8">Buffone et al., 2018</xref>; <xref ref-type="bibr" rid="bib17">Di Nunzio, 2013</xref>; <xref ref-type="bibr" rid="bib16">Di Nunzio et al., 2012</xref>; <xref ref-type="bibr" rid="bib33">Lelek et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Matreyek et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Price et al., 2014</xref>). Recent studies suggest that HIV uses multiple FG regions of several nucleoporins to translocate through the NPC, acting as a chaperone by itself (<xref ref-type="bibr" rid="bib15">Dickson et al., 2024</xref>; <xref ref-type="bibr" rid="bib24">Fu et al., 2024</xref>). Using a reductionist system of Nup98 condensates, it has been demonstrated that FG-mediated phase partitioning identifies specific sites on the capsid that allow it to interact autonomously with these phases. These findings complement the evolving understanding of the early stages of HIV infection, which has been revisited in recent years. They unveil that crucial stages of early viral infection occur within the host nucleus (<xref ref-type="bibr" rid="bib9">Burdick et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Dharan et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Francis et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>; <xref ref-type="bibr" rid="bib57">Selyutina et al., 2020</xref>). Notably, it has been shown that the pre-integration complex forms within the host nucleus (<xref ref-type="bibr" rid="bib42">Müller et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>), and incoming viral RNA genomes accumulate in nuclear niches containing cleavage and polyadenylation specificity factor subunit 6 (CPSF6), RNA-binding protein SON and splicing component, 35 kDa SC35, also known as serine/arginine-rich splicing factor 2 (SRSF2) (<xref ref-type="bibr" rid="bib22">Francis et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>). However, the mechanistic requirements that govern post-nuclear entry phases, which are crucial for a successful viral infection and the establishment of viral reservoirs, remain enigmatic.</p><p>Specifically, the mechanism underlying the formation of nuclear niches containing viral components and nuclear speckle (NS) factors, such as SC35—traditionally used as a marker for NS, remains unclear. However, recent studies have revealed that SON and serine/arginine repetitive matrix protein 2 (SRRM2) are essential for NS biogenesis (<xref ref-type="bibr" rid="bib23">Fu and Maniatis, 1990</xref>). Particularly, intrinsically disordered regions (IDRs) play a critical role in the NS formation (<xref ref-type="bibr" rid="bib29">Ilik et al., 2020</xref>). These membraneless organelles (MLOs) fulfil various cellular functions besides splicing. Recent evidence indicates a direct role of NSs in cellular transcription regulation, as their spatial proximity correlates with gene expression amplification, as demonstrated by live-cell imaging of heat-shock responsive genes (<xref ref-type="bibr" rid="bib11">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="bib65">Zhang et al., 2021</xref>). HIV, being a virus capable of generating new particles through splicing and integrating into active host genes, finds NSs highly conducive for viral replication. HIV particles, along with their RNA genome, accumulate within nuclear MLOs enriched in NS factors (<xref ref-type="bibr" rid="bib2">Ay et al., 2025</xref>; <xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>). Notably, CPSF6, a paraspeckle factor first identified as a viral partner by KewalRamani’s laboratory (<xref ref-type="bibr" rid="bib32">Lee et al., 2010</xref>), has been clearly detected in HIV-induced CPSF6 puncta (<xref ref-type="bibr" rid="bib2">Ay et al., 2025</xref>; <xref ref-type="bibr" rid="bib22">Francis et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Lee et al., 2010</xref>; <xref ref-type="bibr" rid="bib37">Luchsinger et al., 2023</xref>; <xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>). These puncta serve as hubs for nuclear reverse transcription and the formation of pre-integration complexes, which generate active proviruses detected outside but in close proximity to NSs (<xref ref-type="bibr" rid="bib2">Ay et al., 2025</xref>; <xref ref-type="bibr" rid="bib35">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>).</p><p>In our study, we aim to elucidate how HIV-induced CPSF6 puncta form and identify the NS factors involved in their formation. CPSF6, along with NS factors, contains IDRs that can guide HIV-1 to the correct nuclear location for successful infection or allow the virus to remain sequestered during drug treatment, forming reservoirs. Importantly, viral reservoirs are the major bottleneck for curing the infection.</p><p>In this study, we investigate which disordered domain of CPSF6 is responsible for the recruitment of the viral core and generation of HIV-induced CPSF6 puncta in the host nucleus. Simultaneously, we elucidate the key component of NSs that, through its IDRs, enables fusion with HIV-induced CPSF6 puncta, likely stabilizing them. Notably, we observed that the virus rebounds when anti-reverse transcription drugs are removed, but only if nuclear niches containing HIV, NS factors, and CPSF6 are present. If these niches are pharmacologically dismantled, viral rebound does not occur.</p><p>Overall, studying the biogenesis of HIV-induced nuclear niches is crucial for understanding how the virus navigates and persists in the nucleus of infected cells, and for designing new antiretroviral strategies.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Critical role of HIV-induced CPSF6 puncta in restoring nuclear reverse transcription after anti-reverse transcriptase (RT) therapy discontinuation</title><p>Upon nuclear entry, HIV enhances the formation of CPSF6 puncta, where reverse transcription ends. The treatment with the reversible RT inhibitor nevirapine (NVP) can trap the viral RNA genome in these nuclear niches (<xref ref-type="bibr" rid="bib2">Ay et al., 2025</xref>; <xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>). Once NVP is removed, the trapped vRNA can resume RT entirely within the nucleus, a process we term nuclear reverse transcription. Here we demonstrate that this phenomenon depends on the presence of CPSF6 puncta, which are mainly composed of CPSF6 proteins and viral cores. Disruption of these puncta by high doses of PF74 (25 µM) significantly impairs the rebound of the RT, as evidenced by the absence of luciferase expression, similar to what is observed with complete NVP treatment (<xref ref-type="fig" rid="fig1">Figure 1A, B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Role of HIV-induced CPSF6 puncta in the nuclear reverse transcription upon removal of NVP.</title><p>(<bold>A</bold>) THP-1 cells, infected with VSV-G ∆env HIV-1 (NL4.3) ∆R LUC (MOI 10) in presence or not of Nevirapine (10 µM) for 5 days, or in presence of Nevirapine (10 µM) for 2 days and then the remaining 3 days without drug or in presence of Nevirapine (10 µM) for 2 days then in presence of PF74 (25 µM). Confocal microscopy images, to verify the presence of CPSF6 puncta, the cells are stained with anti-CPSF6 antibody (green). Nuclei are stained with Hoechst (blue). Scale bar 10 µm. (<bold>B</bold>) Luciferase assay, to verify luciferase expression in the aforementioned samples. Luciferase values were normalized by total proteins revealed with the Bradford kit. One-way ANOVA statistical test with multiple comparison was performed (****p &lt; 0.0001; *p &lt; 0.05; ns, p &gt; 0.05). Data are representative of two independent experiments. (<bold>C</bold>) Western blots demonstrate CPSF6 depletion using a specific antibody against CPSF6 in THP-1 cells subjected to CRISPR–Cas9 methods: CRISPR–Cas9 bulk (left), and CRISPR–Cas9 clones selected by limiting dilution (right). Each condition is normalized for actin labelling. The ratio between the intensity signal of CPSF6 and actin was analysed via ImageJ and is plotted below each western blot. (<bold>D</bold>) Confocal microscopy images of THP-1 ctrl CRISPR clone 2 cells (Ctrl 2) and THP-1 duplex1-2-3 CRISPR clone 4 cells (CPSF6 KO 4) infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI 10) in the presence of Nevirapine (10 µM). The cells are stained 30 hr p.i. with anti-CPSF6 antibody and anti-HA antibodies to detect HA tagged integrase (IN).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig1-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig1-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata6"><label>Figure 1—source data 6.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig1-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Multiple examples of confocal microscopy images of THP-1 ctrl CRISPR clone 2 cells and THP-1 CPSF6 KO 4 cells infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI 10) in the presence of Nevirapine (10 µM).</title><p>The cells are stained 30 hr p.i. with CPSF6 (green) and HA (red) antibodies to detect integrase (IN).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Multiple examples of THP-1 CPSF6 KO clone 4 cells transduced with different LVs carrying CPSF6 WT or mutants and stained with CPSF6 and HA antibody 30 hr p.i.</title><p>Scale bar 5 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig1-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>CPSF6 FG domain is required for HIV-induced puncta formation</title><p>Formation of CPSF6 puncta upon HIV-1 infection hinges on two key events: the entry of the HIV-1 core into the nucleus and the binding of CPSF6 to the HIV-1 core (<xref ref-type="bibr" rid="bib7">Blanco-Rodriguez and Di Nunzio, 2021</xref>; <xref ref-type="bibr" rid="bib6">Blanco-Rodriguez et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Buffone et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Zila et al., 2021</xref>). To determine the contribution of CPSF6’s disordered domains to the formation of CPSF6 puncta upon HIV-1 infection, we correlated the binding of CPSF6 to the HIV-1 core with the formation of CPSF6 puncta. To this end, we first generated CPSF6 knockout (KO) THP-1 cells (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>) to eliminate the interference from the endogenous protein, which could affect the interpretation of results regarding the role of the analysed CPSF6 domains. CPSF6 depletion in THP-1 cells was performed by CRISPR–Cas9 technology. To completely eliminate the expression of the CPSF6 gene, we selected single clones by limiting dilution. We identified a clone that was completely KO for CPSF6, confirmed through western blot and immunofluorescence (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>), and we infected this clone and the control clone with HIV. CPSF6 puncta were detected only in the control-infected cells and not in the KO clone (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The viral integrase (IN) was observed within CPSF6 puncta, consistent with previous studies (<xref ref-type="bibr" rid="bib22">Francis et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>), but absent in CPSF6 KO cells where viral IN was observed in the cytoplasm (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Thus, we used KO cells for CPSF6 to assess the role of selected CPSF6 domains in HIV-induced condensates (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). We designed various CPSF6 deletion mutants (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) to specifically assess the significance of the main disordered regions of CPSF6 protein (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) such as the FG (phenylalanine and glycine) motif, the low complexity regions (LCRs), and the mixed charge domain (MCD), in the ability of CPSF6 to bind to the core and facilitate the formation of CPSF6 puncta. We investigated the role of the FG peptide by generating a mutant that exclusively lacks the FG peptide (∆FG). Previous in vitro studies have shown that the FG peptide binds to the hydrophobic pocket formed between capsid hexamers (<xref ref-type="bibr" rid="bib8">Buffone et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Price et al., 2014</xref>). Here, we want to investigate the role of FG peptide in the context of the protein during the viral infection.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Role of CPSF6 domains in HIV-induced CPSF6 puncta.</title><p>(<bold>A</bold>) Schema of CPSF6 isoform 588 aa deletion mutants. (<bold>B</bold>) Confocal microscopy images of THP-1 CPSF6 KO cells, transduced with different mutants of CPSF6, infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI 10) in presence of Nevirapine (10 µM). The cells are stained with CPSF6 and HA antibody 30 hr p.i. Scale bar 5 µm. (<bold>C</bold>) Analysis of the number of CPSF6 puncta in THP-1 CPSF6 KO cells transduced with different mutants of CPSF6, not infected or infected in the presence of Nevirapine (10 µM) (the number of analysed cells is shown under the <italic>x</italic>-axis). Statistical test: ordinary one-way ANOVA (****p &lt; 0.0001; ***p &lt; 0.001; *p &lt; 0.05; ns, p &gt; 0.05). (<bold>D</bold>) The plot compares the number of CPSF6 puncta per cell in THP-1 CPSF6 KO cells transduced with different mutants of CPSF6, infected with HIV-1 in the presence of Nevirapine (10 µM). Statistical test: ordinary one-way ANOVA (****p &lt; 0.0001; ns, p &gt; 0.05). (<bold>E</bold>) Confocal microscopy images of THP-1 CPSF6 KO clone 4, non-transduced and non-infected or transduced with WT CPSF6 and CPSF6 3xNLSΔMCD and infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI 10) in presence of Nevirapine (10 µM). Immuno-RNA FISH: the cells are stained with CPSF6 (green) antibody and with 24 probes against HIV-1 Pol sequence (grey) (RNA-FISH) 25 hr p.i. Nuclei are stained with Hoechst (blue). Scale bar 10 µm. Violin plot presenting the percentage of CPSF6 puncta colocalizing with the viral RNA in THP-1 CPSF6 KO clone 4 cells transduced with LVs expressing CPSF6 WT or CPSF6 3xNLSΔMCD (respectively, <italic>n</italic> = 73 and <italic>n</italic> = 103) and infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI 10) in presence of Nevirapine (10 µM). A total of 198 CPSF6 WT puncta and 264 CPSF6 3xNLSΔMCD puncta were counted. Statistical test: unpaired <italic>t</italic>-test, ns, p &gt; 0.05. (<bold>F</bold>) Confocal microscopy images of THP-1 KO CPSF6 cells transduced with WT CPSF6 and CPSF6 ∆MCD without NLS, with 3xNLS or with PY NLS, respectively. Cells were differentiated for 3 days, transduced with CPSF6 lentiviral vectors (MOI 1) for 3 days and infected for 24 hr with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI 10) in the presence of Nevirapine (10 µM). The panels show transduced and uninfected cells. CPSF6 and the IN tagged with the HA are labelled with anti-CPSF6 (green) and anti-HA (white) antibodies, respectively. Nuclei are stained with Hoechst (blue). The arrows show CPSF6 puncta in colocalization with IN-HA. Scale bar 10 µm.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig2-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2—source data 4.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig2-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata5"><label>Figure 2—source data 5.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig2-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata6"><label>Figure 2—source data 6.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig2-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Per-residue intrinsic disorder propensity of the CPSF6 isoform 588 aa evaluated by the Rapid Intrinsic Disorder Analysis Online platform (RIDAO) (<xref ref-type="bibr" rid="bib12">Dayhoff and Uversky, 2022</xref>) that yields results for IU-Pred_short (yellow line), IUPred_long (blue line), PONDR VL3 (green line), PONDR VLXT (black line), PONDR VSL2 (red line), and PONDR FIT (pink line) and computes a mean disorder score for each residue based on these predictors (MDP, thick, dark pink, dashed line).</title><p>Light pink shadow represents MDP error distribution. The thin black line at the disorder score of 0.5 is the threshold between order and disorder, where residues/regions with disorder scores above 0.5 are disordered, and residues/regions below 0.5 are ordered. The dashed line at the disorder score of 0.15 is the threshold between order and flexibility, where residues/regions above 0.15 are flexible, and residues/regions below 0.15 are highly ordered (upper). Schema of the deletion mutants of CPSF6 (bottom).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Lentiviral vector transduction of phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells expressing CPSF6 ∆MCD fused to mNeonGreen (left), CPSF6 NLS∆MCD fused to mNeonGreen (centre), and CPSF6 3xNLS∆MCD fused to mNeonGreen (right).</title><p>CPSF6 is represented in green, and nuclei are stained in blue. Scale bar 5 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig2-figsupp2-v1.tif"/></fig></fig-group><p>To further explore this, we developed an alternative plasmid by expanding the FG peptide deletion to include surrounding prion-like LCRs (∆FG ∆LCR). These regions, outside the CPSF6 context, have been identified as crucial for facilitating strong CPSF6 binding to capsid lattices (<xref ref-type="bibr" rid="bib62">Wei et al., 2022</xref>). In our study, we aim to evaluate their role within a more physiological setting. Additionally, we assessed a CPSF6 variant that carries the 15-mer FG peptide flanked by non-LCR sequences, such as those derived from Beta-adducin (ADD2), kindly provided by Mamuka Kvaratskhelia (∆LCR + ADD2). These protein segments are known for their high flexibility, akin to the LCR of CPSF6. Furthermore, to elucidate the contribution of the LCRs of CPSF6 in the formation of CPSF6 puncta, we generated a mutant lacking both LCRs (∆LCR). Analysis of the MCD contribution to both the ability of CPSF6 to bind to the core and formation of CPSF6 puncta was achieved by deleting the MCD and adding 3 nuclear localization signals (3xNLS ∆MCD) since the deletion of the MCD results in a protein that localizes mainly into the cytoplasm (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>).</p><p>To correlate the ability of CPSF6 to bind to the HIV-1 core with formation of CPSF6 puncta, we expressed wild-type and mutant CPSF6 constructs in THP-1 cells knockout for CPSF6. Subsequently, we infected these cells with HIV-1 and analysed the presence or absence of CPSF6 puncta at 24 hr post-infection. Importantly, for the imaging experiment, we expressed CPSF6 WT and mutants without tags to avoid the formation of aggregates that could interfere with our conclusions. Our data show that HIV-induced CPSF6 puncta can form extremely rarely with the deletion mutant CPSF6 ADD2∆LCR and with the mutant lacking the FG or both the FG peptide and the LCRs (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). However, when we analysed the role of the MCD domain in CPSF6 puncta formation, which was indicated to be important for condensing CPSF6 in NS (<xref ref-type="bibr" rid="bib26">Greig et al., 2020</xref>), comparing the number of CPSF6 WT puncta induced by HIV infection with CPSF6 mutants revealed that the MCD domain does not play a critical role in HIV-induced CPSF6 puncta formation (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>). In addition, we observed that the majority of analysed CPSF6 3xNLS∆MCD puncta contain vRNA inside, similar to CPSF6 WT puncta (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), thus corroborating the lack of a role for this intrinsically disordered domain in HIV-induced CPSF6 puncta. Since the NLS domain from SV40, which replaces the MCD, is highly basic and could potentially induce condensates, we fused CPSF6 with a non-basic NLS (PY-NLS) or removed the NLS entirely. Even though these two proteins do not efficiently enter the nucleus, the few that do manage to reach the nucleus can host viral particles, as evidenced by the presence of IN. Many viruses are typically blocked in the cytoplasm due to the presence of these mutants that are mainly cytoplasmic. However, because we used a high viral dose, the blockage in the cytoplasm was not complete. As a result, the viruses that successfully entered the nucleus induced the formation of puncta associated with CPSF6-deleted mutants, indicating that the MCD is not critical for the formation of HIV-induced CPSF6 puncta (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Similar to the MCD, when we compared CPSF6 truncated for the LCRs with CPSF6 WT, we observed that the LCRs do not contribute to CPSF6 puncta formation. Therefore, the FG peptide alone, without the LCRs, is the only CPSF6 domain required for their formation (<xref ref-type="fig" rid="fig2">Figure 2B–F</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p><p>Next, we tested the ability of the different CPSF6 deletion mutants for their ability to bind the viral core using a previously described capsid binding assay (<xref ref-type="bibr" rid="bib56">Selyutina et al., 2018</xref>). Wild-type and mutant CPSF6 proteins were expressed in human 293T cells at similar levels (INPUT) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Extracts containing wild-type and mutant CPSF6 proteins were incubated with stabilized HIV-1 capsid tubes for 1 hr at 25°C in the presence of 10 µM of PF74, which is a small molecule that competes with CPSF6 for binding to the hydrophobic pocket formed between hexamers that constitute the viral core (<xref ref-type="bibr" rid="bib8">Buffone et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Price et al., 2014</xref>). HIV-1 capsid stabilized tubes were washed, and the bound proteins were eluted using Laemli buffer (BOUND). For every construct, the percentage of bound protein relative to input in the presence or absence of PF74 is shown (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Our results revealed that the absence of the FG peptide (∆FG) entirely abolished CPSF6’s ability to bind to the viral core. In agreement, simultaneous deletion of the FG motif and LCRs (∆FG ∆LCR) resulted in a construct unable to bind to the viral core. Similar outcomes were observed when the LCRs were replaced with sequences derived from ADD2, even if the FG was present.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Evaluation of CPSF6 deletion mutants’ binding capacity to the viral core.</title><p>(<bold>A</bold>) Ability of wild-type and mutant CPSF6 proteins to bind to the HIV-1 core. Cellular extracts derived from human 293T cells expressing similar levels of the indicated CPSF6 proteins (INPUT) were incubated with HIV-1 capsid stabilized tubes for 1 hr at room temperatures in the presence and absence of 10 µM PF74, as described in materials and methods. As a carrier control, we utilized DMSO. Subsequently, HIV-1 capsid stabilized tubes were washed, and the bound proteins were eluted 1X Laemmli buffer 1X. The BOUND fractions were analysed by western blotting using antibodies against neon-GFP and the HIV-1 capsid. (<bold>B</bold>) Experiments were repeated at least three times and the average BOUND fraction relative to the INPUT fraction normalized to wild-type binding is shown for the different CPSF6 mutants. *** indicates a p-value &lt;0.001; **** indicates a p-value &lt;0.0001; and ns indicates no significant difference as determined by unpaired <italic>t</italic>-tests.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig3-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig3-v1.tif"/></fig><p>LCR-FG is notably more disordered than ADD2-FG, containing a high proportion of prolines (48 out of 98 residues), which makes it mostly non-foldable (<xref ref-type="fig" rid="fig4">Figure 4A–H</xref>). Since proline is a structure-disrupting residue, LRC-FG is not expected to adopt any secondary structure. In contrast, ADD2-FG contains fewer prolines (15 out of 98 residues) but has many charged residues. It is predicted to form two short α helices and a β strand, arranged as: α helix–FG–β strand–α helix (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). ADD2-FG may form a flexible collapsed state, as its oppositely charged residues are evenly distributed, potentially allowing polyelectrostatic compaction. This suggests that FG within ADD2-FG may be less accessible for the interaction with the viral core’s hydrophobic pocket due to its involvement in this collapsed conformational ensemble (<xref ref-type="fig" rid="fig4">Figure 4A–E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). This aligns with the inability of CPSF6 carrying ADD2 in place of the LCRs to induce CPSF6 puncta (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). On the other hand, the deletion of only the two LCRs, while keeping the FG peptide intact, resulted in unexpected findings. The ∆LCR mutant exhibited a stronger binding affinity for the viral core when compared to the wild-type protein (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). These results suggest that the LCRs surrounding the FG motif are modulating the affinity of CPSF6 to the viral core, which might be important for function. By contrast, deletion of the MCD (∆MCD) but retention of other regions, such as the FG peptide and the LCRs, demonstrated a binding affinity to the viral core similar to that of the wild-type protein. These results suggest that the MCD domain is not involved in the binding of CPSF6 to the viral core, which is not surprising since the CPSF6 (1–358), which does not have an MCD, binds to the viral core (<xref ref-type="bibr" rid="bib32">Lee et al., 2010</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Comparison of second structures of ADD2 and low-complexity region (LCR).</title><p>(<bold>A</bold>) Physicochemical characteristics of the LCR-FG and ADD2-FG sequences. Intrinsic disorder predispositions evaluated by PONDR VLXT. Position of the FR segment within the LCR-FG and ADD2-FG sequences is shown as grey shaded area. (<bold>B</bold>) Linear distribution of the net charge per residue (NCPR) within the LCR-FG sequence evaluated by CIDER. (<bold>C</bold>) Linear distribution of the NCPR within the ADD2-FG sequence evaluated by CIDER. (<bold>D</bold>) Secondary structure propensity of the LCR-FG sequence evaluated by PSIPRED. (<bold>E</bold>) Secondary structure propensity of the ADD2-FG sequence evaluated by PSIPRED. (<bold>F</bold>) Analysis of the peculiarities of the amino acid compositions of the intrinsically disordered C-terminal domain (residues 261–358) of human CPSF6 and its different mutants. Relative abundance of prion-like LCR defining uncharged residues in analysed protein segments. (<bold>G</bold>) Relative abundance of proline residues in analysed protein segments. (<bold>H</bold>) Relative abundance of charged residues in analysed protein segments. The values were calculated by dividing numbers of prion-like LCR defining uncharged (Ala, Gly, Val, Phe, Tyr, Leu, Ile, Ser, Thr, Pro, Asn, Gln, Pro) and charged (Asp, Glu, Lys, Arg) residues by the total number of amino acids in the respective protein fragments. Corresponding values for all protein sequences deposited in the UniProtKB/Swiss-Prot database, PDB Select25, and DisProt are shown for comparison.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Sequences of FG and low-complexity regions (LCRs) or substituted amino acid sequences analysed in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Thus, the viral capsid, through the FG peptide of CPSF6, constitutes the scaffold of HIV-induced CPSF6 puncta.</p><p>In summary, our results suggest that the FG peptide is the main determinant involved in the binding of CPSF6 to the viral capsid. Interestingly, our work implies that the LCRs may be modulating the affinity of the FG motif for the viral core (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Recognition motifs that mediate protein-protein interactions, such as the FG motif of CPSF6, are usually embedded within longer IDRs that can modulate affinity of the interaction (<xref ref-type="bibr" rid="bib31">Karlsson et al., 2022</xref>). Taken together, our data show that the FG peptide coordinates both the binding to the viral core and the induction of CPSF6 puncta. This coordination suggests that the FG peptide plays a critical dual role in recognizing the viral capsid and facilitating the cellular clustering of CPSF6, which may be part of the cellular response to viral entry.</p></sec><sec id="s2-3"><title>Role of FG domain in viral replication</title><p>We aimed to investigate the role of the FG domain of CPSF6 in viral infection. To correctly perform the infectivity assay, we generated stable cell clones expressing protein levels comparable to WT cells (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>). Importantly, we assessed the reproducibility of our experiments by freezing and thawing these clones. Thus, we performed infectivity assays in THP-1 macrophage-like cells WT, KO for CPSF6 or complemented with CPSF6∆FG, using both a single-round virus and a replication-competent virus. The results, shown in <xref ref-type="fig" rid="fig5">Figure 5C, D</xref>, indicate that complete depletion of CPSF6 reduces infectivity, as measured by luciferase expression in a single-round infection (KO: ~65%; ΔFG: ~74%; compared to WT: 100% on average). Notably, a more pronounced defect in viral particle production was observed when WT virus was used for infection (KO: ~21%; ΔFG: ~16%; compared to WT: 100% on average). According to our results, depletion of full-length CPSF6, or expression of a CPSF6 variant lacking only the FG domain, both reduce viral infection compared to cells expressing full-length CPSF6, indicating that the FG domain plays an important role in HIV-1 infection.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Role of FG motif in viral replication.</title><p>(<bold>A</bold>) WB showing CPSF6 protein from several single clones derived from CPSF6 KO clone obtained upon complementation with CPSF6 ∆FG and normalized with beta-actin. (<bold>B</bold>) Quantification of the expression of CPSF6 ∆FG protein in different single clones compared to CPSF6 WT (value 1). (<bold>C</bold>) Infectivity assay using a single-round infectious virus carrying the cDNA of Luciferase as reporter gene. Values are expressed as % of RLU compared to WT cells. (<bold>D</bold>) Infectivity assay of a replication competent virus: vRNA from new viruses produced after infection of WT, CPSF6 KO, and CPSF6∆FG cells was analysed and shown in the histograms as % of vRNA copies compared to vRNA in WT THP-1 cells considered 100%.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig5-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig5-v1.tif"/></fig></sec><sec id="s2-4"><title>HIV-induced CPSF6 mutants puncta and NSs</title><p>The NS factor SC35, commonly used as a marker of NS, has been detected in HIV-induced CPSF6 puncta (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). In this study, we investigated whether HIV-induced CPSF6 mutant puncta are associated with SC35. We infected cells expressing CPSF6 WT, CPSF6 3xNLS ∆MCD, CPSF6 ∆LCR, CPSF6 ∆MCD, and CPSF6 PY NLS ∆MCD, and examined whether the nuclear puncta formed by the various CPSF6 proteins associate with SC35. Imaging analysis revealed no significant difference in the association of SC35 with CPSF6 WT or the CPSF6 mutants (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), confirming that the disordered domains, LCRs and MCDs, are dispensable for the formation of HIV-induced CPSF6 puncta that localize in the canonical nuclear niches marked by SC35.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Depletion of mixed charge domain (MCD) or low-complexity region (LCR) does not affect the formation of HIV-induced CPSF6 puncta.</title><p>(<bold>A</bold>) Epifluorescence microscopy images of both infected and non-infected differentiated THP-1 cells showing the presence of CPSF6 puncta only in the infected condition. CPSF6 and SC35 are labelled with anti-CPSF6 (green) and anti-SC35 (red) antibodies, respectively. Nuclei are stained with Hoechst (blue). Scale bar 10 µm. (<bold>B</bold>) Confocal microscopy images of THP-1 KO CPSF6 cells, differentiated for 3 days, transduced with CPSF6 lentiviral vector (MOI 1) (specifically WT CPSF6, CPSF6 ∆LCRs, CPSF6 ∆MCD with 3xNLS, without NLS, or with PY NLS) for 3 days and infected for 24 hr with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx MOI 10 in presence of Nevirapine (10 µM). CPSF6 and nuclear speckles were labelled with anti-CPSF6 (green) and anti-SC35 (red) antibodies, respectively. Nuclei are stained with Hoechst (blue). Scale bar 10 µm. The percentage of CPSF6 puncta associated with SC35 per field of view is shown in the graph. <italic>N</italic> cells were counted in each condition and a one-way ANOVA statistical test with multiple comparison was performed; ns, p-value &gt;0.05.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig6-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig6-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig6-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata5"><label>Figure 6—source data 5.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig6-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig6-v1.tif"/></fig></sec><sec id="s2-5"><title>Biogenesis of HIV-induced CPSF6 puncta carrying NS factors</title><p>NS factors, particularly those involved in their biogenesis, such as SON and SRRM2 (<xref ref-type="bibr" rid="bib29">Ilik et al., 2020</xref>), have been identified as constituents of HIV-induced CPSF6 puncta. However, the specific role of NSs in these puncta remains unclear. Most of the existing results have been obtained through immunofluorescence experiments conducted several days post-infection. In this study, we conducted a time course experiment to investigate the biogenesis of HIV-induced CPSF6 puncta, which contain NS factors. Our goal was to capture the fusion event between the HIV-induced CPSF6 puncta and NS, providing insights into the dynamics of how HIV manipulates host nuclear structures during infection. We hypothesized that NS factors might either be recruited during the initial formation of HIV-induced CPSF6 puncta, shortly after the virus is released from the nuclear basket of the NPC, or later via the fusion between NSs and HIV-induced CPSF6 puncta. To investigate this, we performed live imaging to track CPSF6-mNeonGreen and NSs in cells expressing endogenous SRRM2 fused with a Halo tag, using CRISPR Paint (courtesy of Roy Parker) (<xref ref-type="bibr" rid="bib34">Lester et al., 2021</xref>). We fixed and labelled samples at different time points post-infection, ranging from 6 to 30 h.p.i. (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1</xref> and <xref ref-type="fig" rid="fig7s2">2</xref>). At 6 h.p.i., 27% of HIV-induced CPSF6 puncta were still individual, compared to only 9% at 30 h.p.i. (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Concurrently, 61% of HIV-induced CPSF6 puncta were fused with NS at 6 h.p.i., rising to 75% at 30 h.p.i. (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). This indicates a progressive increase in the number of HIV-induced CPSF6 puncta fusing with NS over time (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Overall, we detected individual CPSF6 puncta (green) and NSs (red) that quickly fused, confirming that this fusion occurs within the two independent puncta, CPSF6 and SRRM2, rather than during the formation of HIV-induced CPSF6 puncta (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>, <xref ref-type="video" rid="fig7video1 fig7video2">Figure 7—videos 1 and 2</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Dynamics of the HIV-induced CPSF6 puncta formation and their fusion with NSs.</title><p>(<bold>A</bold>) Time course of infection of THP-1, 6, 9, 12, 30 h.p.i., or non-infected. Cells were stained with antibodies against CPSF6 (green) and SC35 (red). (<bold>B</bold>) The graph shows the percentage of CPSF6 puncta associated with nuclear speckle (NS) or adjacent to NS or isolated from NS at different time post-infection. (<bold>C</bold>) The graph shows the progression of CPSF6 puncta associated with NS during the time post-infection. <italic>N</italic> indicates the number of cells analysed. One-way ANOVA statistical test with multiple comparison was performed; ns, p-value &gt;0.05; **** indicates a p-value &lt;0.0001.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig7-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig7-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata3"><label>Figure 7—source data 3.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig7-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>THP-1 infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx were labelled after 6, 9, 12, 30 h.p.i. with specific antibodies against CPSF6 (green) and SC35 (red), nuclei are stained with Hoechst (blue).</title><p>Scale bar 10 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Timelapse of <xref ref-type="video" rid="fig7video2">Figure 7—video 2</xref> which recapitulates the key steps of the dynamics of HIV-induced-CPSF6 puncta biogenesis.</title><p>CPSF6 was visualized transducing HEK293 SRRM2 HaloTag cells for 24 hr with CPSF6-mNeonGreen lentiviral vector (MOI 0.5). SRRM2-HaloTag allowed the use of TMR-Halo Tag Ligand to visualize the SRRM2 membraneless organelles (MLOs). After 9 hr after VSV-G/ΔEnvHIV-1 LAI (BRU) (MOI 10) infection in the presence of Nevirapine, CPSF6 puncta formed independently (9 h 01 m), migrating afterwards to the SRRM2 MLOs and leading to a final fusion between CPSF6 puncta and SRRM2 MLOs (9h14m).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig7-figsupp2-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-103725-fig7-video1.mp4" id="fig7video1"><label>Figure 7—video 1.</label><caption><title>CPSF6 membraneless organelles (MLOs) can form independently from SRRM2 MLOs in HEK293 SRRM2 HaloTag cells.</title><p>Spinning disk confocal images of HEK293 SRRM2 HaloTag cells acquired 9 hr after VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) (MOI 10) infection occurred in the presence of Nevirapine (10 µM). Cells were previously transduced for 24 hr with CPSF6-mNeonGreen lentiviral vector (MOI 0.5) to detect CPSF6 (visualized in green). SRRM2 MLOs were detected using the TMR-HaloTag Ligand (in red) and the nuclei were stained with Hoechst (blue). Acquisitions were performed continuously for 27 min, which allowed us to see the independent formation of CPSF6 puncta, their migration towards the SRRM2 MLOs and the final fusion of CPSF6 puncta and SRRM2 MLOs.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-103725-fig7-video2.mp4" id="fig7video2"><label>Figure 7—video 2.</label><caption><title>CPSF6 membraneless organelles (MLOs) can form independently from SRRM2 MLOs in HEK293 SRRM2 HaloTag cells.</title><p>Spinning disk confocal images of HEK293 SRRM2 HaloTag cells acquired 9 hr after VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) (MOI 10) infection occurred in the presence of Nevirapine (10 µM). Cells were previously transduced for 24 hr with CPSF6-mNeonGreen lentiviral vector (MOI 0.5) to detect CPSF6 (visualized in green). SRRM2 MLOs were detected using the TMR-HaloTag Ligand (in red) and the nuclei were stained with Hoechst (blue). Acquisitions were performed continuously for 27 min, which allowed us to see the independent formation of CPSF6 puncta, their migration towards the SRRM2 MLOs and the final fusion of CPSF6 puncta and SRRM2 MLOs.</p></caption></media></fig-group><p>Taken together, these results suggest that HIV-induced CPSF6 puncta first form independently of NS and later fuse with NS, causing an enlargement of NS as part of the hijacking process by HIV-1.</p></sec><sec id="s2-6"><title>Role of SON and SRRM2 in the fusion and stabilization of HIV-induced CPSF6 puncta within NSs</title><p>Macrophage-like cells, THP-1, were depleted for SON or SRRM2 using AUM<italic>silence</italic> ASO technology (<xref ref-type="bibr" rid="bib25">Gao et al., 2024</xref>; <xref ref-type="bibr" rid="bib38">Marasca et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Mazzeo et al., 2024</xref>; <xref ref-type="bibr" rid="bib66">Zhang et al., 2023</xref>). The level of depletion of SON and SRRM2 was evaluated by immunofluorescence and western blot using antibodies against SON and SRRM2 (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Both depleted cells were analysed also for the presence of NS, labelled by SC35 (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). However, recent findings suggest that the primary target of the SC35 mAb is SRRM2 (<xref ref-type="bibr" rid="bib29">Ilik et al., 2020</xref>). To confirm this, cells depleted of SRRM2 were labelled with antibodies against both SRRM2 and SC35 (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). We have observed that the reduction of SRRM2 resulted in a slight decrease in the mean intensity of SC35, whereas the depletion of SON (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>) did not have the same effect.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Role of SRRM2 and SON in the formation of HIV-induced CPSF6 puncta.</title><p>(<bold>A</bold>) Depletion of SON and SRRM2 in THP-1 cells using AUM<italic>silence</italic> ASO technology. The degree of depletion is quantified by WB and the mean intensity through immunofluorescence using antibodies against SON and SRRM2, respectively. Scale bar 5 µm. (<bold>B</bold>) The percentage of CPSF6 puncta formation is quantified by IF in THP-1 cells knocked down for SON, SRRM2, and control (Ctrl) infected with HIV-1 (MOI 25) for 48 hr. CPSF6 is stained with an antibody against CPSF6 (green), and nuclei are stained with Hoechst (blue). The graph on the right reports the percentage of CPSF6 puncta calculated from more than 100 cells. Scale bar 10 µm. Experiments were performed at least twice. (<bold>C</bold>) (Top panels) Confocal microscopy images of ∆IDR HaloTag SRRM2 HEK293 and HaloTag SRRM2 HEK293 cells stained with the halo tag ligand (red), and nuclei (blue). Scale bar 10 µm. (Bottom panels) Confocal microscopy images of HaloTag SRRM2 HEK293 and ∆IDR HaloTag SRRM2 HEK293 cells, both labelled with anti-SRRM2 (red) and anti-SON (grey) antibodies. Nuclei are stained with Hoechst (blue). Scale bar 10 µm. Statistical studies are summarized in the violin plot which displays the distribution of the number of SON puncta per cell in the two conditions. <italic>N</italic> cells were counted and Kolmogorov–Smirnov test was performed, ns, p &gt; 0.05. (<bold>D</bold>) Confocal microscopy images of HaloTag SRRM2 HEK293 and ∆IDR HaloTag SRRM2 HEK293 cells, either non-infected or infected for 24 hr with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) (MOI 10) in the presence of Nevirapine (10 µM). CPSF6 and SC35 are labelled with anti-CPSF6 (red) and anti-SC35 (grey) antibodies, respectively. Nuclei are stained with Hoechst (blue). The plot shows the mean ± SD of the percentage of cells with CPSF6 puncta calculated in n fields of view (<italic>n</italic> = 24, 29, 32); <italic>N</italic> is the number of cells analysed for each of the three different cell lines; an unpaired <italic>t</italic>-test was performed, ****p &lt; 0.0001; ns, p &gt; 0.05. Scale bar 10 µm. Experiments were performed at least twice.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-103725-fig8-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig8sdata2"><label>Figure 8—source data 2.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig8-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata3"><label>Figure 8—source data 3.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig8-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata4"><label>Figure 8—source data 4.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig8-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata5"><label>Figure 8—source data 5.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig8-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata6"><label>Figure 8—source data 6.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig8-data6-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata7"><label>Figure 8—source data 7.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig8-data7-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig8sdata8"><label>Figure 8—source data 8.</label><media mimetype="application" mime-subtype="zip" xlink:href="elife-103725-fig8-data8-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Analysis of the mean intensity: SRRM2 depletion is confirmed using antibodies against both (<bold>A</bold>) SC35 and (<bold>B</bold>) SRRM2 by IF.</title><p>Statistical analysis: one-way ANOVA (****p &lt; 0.0001; *p &lt; 0.05; ns, p &gt; 0.05).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig8-figsupp1-v1.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>HEK 293 HaloTag SRRM2 or ∆IDR were labelled with Halo ligand (red) and an anti-SON antibody (grey), nuclei are stained by Hoechst (blue).</title><p>Scale bar 10 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig8-figsupp2-v1.tif"/></fig><fig id="fig8s3" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 3.</label><caption><title>Multiple examples (<bold>A–E</bold>) of confocal microscopy images of HaloTag SRRM2 HEK293 and ∆IDR HaloTag SRRM2 HEK293 cells, either non-infected or infected for 24 hr with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) (MOI 10) in the presence of Nevirapine (10 µM).</title><p>CPSF6 and SC35 are labelled with anti-CPSF6 (red) and anti-SC35 (grey) antibodies, respectively. Nuclei are stained with Hoechst (blue). Scale bar 10 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103725-fig8-figsupp3-v1.tif"/></fig></fig-group><p>Subsequently, we infected THP-1 depleted cells for SRRM2 and SON or control cells with HIV-1 and we fixed them at 48 hr post-infection for immunofluorescence. We calculated the percentage of CPSF6 puncta in HIV-infected THP-1 control cells (approximately 78%) and in HIV-infected THP-1 cells depleted for SRRM2 (about 43%) and SON (around 66%). Results from our experimental conditions indicate that the partial depletion of SRRM2 affects the formation of HIV-induced CPSF6 puncta, while the depletion of SON slightly reduces their establishment (<xref ref-type="fig" rid="fig8">Figure 8B</xref>).</p></sec><sec id="s2-7"><title>The IDR of SRRM2 is a crucial element for the fusion of HIV-induced CPSF6 puncta to the NSs</title><p>CPSF6 contains several disordered regions (<xref ref-type="bibr" rid="bib18">Di Nunzio et al., 2023</xref>) as well as NS factors (<xref ref-type="bibr" rid="bib29">Ilik et al., 2020</xref>). Previous studies have established the role of IDR of SRRM2 in the biogenesis of NS (<xref ref-type="bibr" rid="bib29">Ilik et al., 2020</xref>).</p><p>Here, we investigate the role of IDRs within NS factors, with a specific emphasis on SRRM2, in the fusion and stabilization of HIV-induced CPSF6 puncta. To address this inquiry, we utilized previously published HEK293 cell lines generated using the CRISPaint system (<xref ref-type="bibr" rid="bib34">Lester et al., 2021</xref>), comprising two distinct lines: HaloTag SRRM2, SRRM2 full-length (FL) (1–2748 aa) fused with Halo tag (insertion at amino acid [aa] 2708), and a cell line lacking the C-terminal IDR of SRRM2, known as ∆IDR HaloTag SRRM2 (1–429 aa, with halo insertion at aa 430).</p><p>As anticipated, the truncated form of SRRM2 displayed a more diffuse distribution within the nucleus, without recruitment to NS (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>), and consequently lacked nuclear puncta (<xref ref-type="fig" rid="fig8">Figure 8C</xref>, top panels). On the other hand, the number of SON puncta was highly similar between the two cell lines (<xref ref-type="fig" rid="fig8">Figure 8C</xref>, panels on the bottom, <xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3</xref>).</p><p>Subsequently, we quantified the formation of CPSF6 puncta in both cell lines infected with HIV-1. No significant difference in HIV-induced CPSF6 puncta formation was observed between HEK293 and HEK293 carrying the SRRM2 halo tag (~27%). However, a substantial reduction in HIV-induced CPSF6 puncta was evident in the cell line carrying the SRRM2 form that lacks the IDR (~11%) (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). Collectively, these results underscore the pivotal role of the SRRM2 IDR in the stabilization of HIV-induced CPSF6 puncta through their fusion with NSs (<xref ref-type="fig" rid="fig7">Figure 7A–C</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>HIV-1 capsid has transformed long-standing assumptions in the field. Previously considered an undruggable viral target due to the belief that it disassembled shortly after HIV entered target cells, whereas recent findings have revealed its essential role in nuclear import (<xref ref-type="bibr" rid="bib1">Ay and Di Nunzio, 2023</xref>; <xref ref-type="bibr" rid="bib7">Blanco-Rodriguez and Di Nunzio, 2021</xref>; <xref ref-type="bibr" rid="bib6">Blanco-Rodriguez et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2016</xref>; <xref ref-type="bibr" rid="bib60">Taylor and Fassati, 2024</xref>; <xref ref-type="bibr" rid="bib64">Yamashita and Emerman, 2004</xref>; <xref ref-type="bibr" rid="bib67">Zila et al., 2021</xref>). Notably, the first-in-class antiretroviral capsid inhibitor, Lenacapavir, has shown remarkable results in patients, demonstrating that the capsid, contrary to previous belief, can indeed be a viable therapeutic target. While Lenacapavir improves patients' quality of life with only two injections per year (<xref ref-type="bibr" rid="bib36">Link et al., 2020</xref>; <xref ref-type="bibr" rid="bib55">Segal-Maurer et al., 2022</xref>), no current antiretroviral drugs provide a cure. This may be due to our incomplete understanding of certain aspects of HIV biology. In this study, we shed light on the post-nuclear entry steps, a critical phase for the establishment of viral reservoirs, which represent the main barrier to a cure. Recent findings have shown that not only does the HIV viral capsid translocate through the NPC, but that the viral nuclear entry also enhances the formation of CPSF6 puncta. Additionally, it has been revealed that RT is completed within the nucleus (<xref ref-type="bibr" rid="bib9">Burdick et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Dharan et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>; <xref ref-type="bibr" rid="bib57">Selyutina et al., 2020</xref>). Furthermore, incoming viral RNA has been observed to be sequestered in nuclear niches in cells treated with the reversible RT inhibitor, NVP. When macrophage-like cells are infected in the presence of NVP, the incoming viral RNA is held within the nucleus (<xref ref-type="bibr" rid="bib2">Ay et al., 2025</xref>; <xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref>). This scenario could also occur in patients receiving antiretroviral therapy. Notably, we found that pharmacological dismantling of CPSF6 puncta prevents the restoration of nuclear reverse transcription, indicating that HIV-induced CPSF6 puncta are critical for the viral life cycle. Conversely, THP-1 cells either depleted of CPSF6 or expressing a CPSF6 variant lacking the FG domain exhibit impaired viral replication. Understanding the biogenesis of these puncta could be a significant step towards deepening our knowledge of HIV biology and providing additional tools to combat this pandemic virus.</p><p>Here, we identify the disordered FG peptide essential for the binding with the viral capsid as the inducer of HIV-induced CPSF6 puncta. Notably, CPSF6 protein lacking the FG peptide is incapable of forming nuclear puncta. Moreover, we discovered that the two major IDRs of CPSF6, the MCDs and the LCRs, are dispensable for the formation of viral nuclear puncta. The MCDs of CPSF6 have been shown to provide cohesion for NS condensation (<xref ref-type="bibr" rid="bib26">Greig et al., 2020</xref>). A study performed in HEK293T-derived CPSF6 knockout (CKO) cells (clone B8) complemented with a tagged CPSF6 reported that the MCD is critical for CPSF6 cluster formation (<xref ref-type="bibr" rid="bib30">Jang et al., 2024</xref>). In contrast, we chose to work with a more physiologically relevant cell line for HIV infection, macrophage-like cells, and we employed untagged CPSF6 proteins (WT and deletion mutants) to avoid potential artefacts introduced by protein tagging. Under our experimental conditions, the MCD did not appear to play a critical role in the formation of HIV-induced CPSF6 puncta. CPSF6 puncta induced by CPSF6 depleted for the MCD upon infection are highly similar to those formed by wild-type CPSF6, suggesting that MCDs do not play a significant role in this process. Additionally, the LCRs of CPSF6 also do not appear to influence puncta formation, as their depletion does not reduce the number of CPSF6 puncta. This indicates that neither the MCDs nor the LCRs are involved in CPSF6 puncta formation during HIV infection. Surprisingly, when we assessed the ability of CPSF6 domains to bind to the viral capsid, we observed that the deletion of LCRs increases CPSF6’s ability to bind to the viral capsid. We hypothesize that a change in charges may alter the binding mechanism of CPSF6 when LCRs are absent. In scenarios where the FG motif is depleted, we observed a dramatic inhibition of HIV-induced CPSF6 puncta formation and a lack of binding to the viral core in vitro. On the flip side, the linkage between CPSF6 entities is facilitated by the FG peptides’ interaction with certain hydrophobic CA pockets along adjoining hexamers (<xref ref-type="bibr" rid="bib62">Wei et al., 2022</xref>). Therefore, it’s conceivable that FG peptides, not involved in the capsid’s binding, could coalesce similarly to FG-Nups. These undergo phase separation, forming condensates with NPC-like permeability barrier features (<xref ref-type="bibr" rid="bib28">Hülsmann et al., 2012</xref>).</p><p>We have also identified HIV-induced CPSF6 puncta formation independent of NS at early stages post-infection, with a progressive increase in CPSF6 puncta colocalizing with NS over time. These results were obtained by focusing our studies on two scaffold proteins involved in NS biogenesis: SON and SRRM2. Over the past approximately 0.6–1.2 billion years of metazoan evolution, these two factors have undergone significant lengthening, unlike many other proteins involved in splicing. This extension primarily occurred within their IDRs, which are commonly associated with liquid–liquid phase separation and the formation of biomolecular condensates (<xref ref-type="bibr" rid="bib49">Rai et al., 2018</xref>). Co-depleting SRRM2 with SON, or depleting SON in a cell line where it is deleted the intrinsically disordered C-terminus of SRRM2, abolished the formation of NSs (<xref ref-type="bibr" rid="bib29">Ilik et al., 2020</xref>). However, the depletion of only one factor does not abolish NSs. Consistent with this finding, we observed that the depletion of SRRM2 does not affect the presence of SON nuclear puncta. Similar results were obtained with cells genetically modified to express the truncated form of SRRM2 lacking the IDRs. When the ∆IDR SRRM2-halo tag was detected by the halo ligand, there was no recruitment of the truncated SRRM2 form in NSs. However, if SC35 is used as a target for antibodies, it can still be detected, albeit with a much lower intensity signal than in cells expressing the full-length SRRM2. Additionally, we observed a significant reduction in the detection of HIV-induced CPSF6 puncta. The few CPSF6 puncta detected in these cells colocalized with the weak SC35 signal. These results suggest that the IDR of SRRM2 plays an important role in HIV-induced CPSF6 puncta stabilization, but rare puncta can appear, likely induced by redundant NS factors. This indicates that further investigation is needed to better understand the hijacking of NS by HIV.</p><p>Taken together, our results reveal the intricate interplay between individual CPSF6 domains and the viral capsid in dictating the nuclear fate of the virus. Concurrently, the IDR domain of SRRM2 contributes to the enlargement of particular NSs with the fusion of HIV-induced CPSF6 puncta. Lastly, these HIV-induced CPSF6 puncta necessitate FG peptide to engage the viral core.</p><p>Overall, this study could provide insights into the understanding of viral invasion and persistence within the host.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell lines</title><p>THP-1 cells (ATCC) are immortalized monocytic cells, which, once seeded, differentiate into macrophage-like cells under phorbol 12-myristate 13-acetate (PMA) treatment (160 nM). THP-1 cells were also engineered to knock out CPSF6. These cells were cultivated in RPMI 1640 medium supplemented with 10% foetal bovine serum (FBS) and 1% penicillin–streptomycin solution (100 U/ml). HEK293T cells (ATCC) are human embryonic kidney cells used to produce LVs. For <xref ref-type="fig" rid="fig2">Figure 2</xref>, we used two engineered HEK293 strains, Halo tagged SRRM2 HEK293 cells and Halo tagged SRRM2 ∆IDR HEK293 cells, kind gifts from Roy Parker’s lab (<xref ref-type="bibr" rid="bib34">Lester et al., 2021</xref>), characterized by the Halo tagged SRRM2 protein. In Halo tagged SRRM2 ∆IDR HEK293 cells, Parker’s lab also deleted the SRRM2 sequence encoding for aa 430–2748. All the HEK293 strains were cultivated in Dulbecco’s modified Eagle medium supplemented with 10% FBS and 1% penicillin–streptomycin (100 U/ml). All cells used in the study were tested for mycoplasma and they were negative.</p></sec><sec id="s4-2"><title>Bacteria strains</title><p>All <italic>Escherichia coli</italic> bacteria strains were grown in Luria-Bertani (LB) medium at 37°C. DHα competent cells and Stellar Competent Cells were used for molecular cloning, while <italic>E. coli</italic> One-Shot BL21star (DE3) cells were exploited for protein production.</p></sec><sec id="s4-3"><title>Plasmids</title><p>To express the WT CPSF6/WT CPSF6-mNeonGreen and the mutant CPSF6/mutant CPSF6-mNeonGreen clones, the correspondent coding sequences were engineered in pSICO plasmids. The two original plasmids used were pSICO CPSF6-mNeonGreen and pLPCX CPSF6 ADD2, a gift from Mamuka’s lab. HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) plasmid encodes the ΔEnvHIV-1 LAI (BRU) viral genome where the IN protein is fused to the HA tag while pNL4.3 ∆env ∆Nef IRES GFP plasmid encodes the ΔEnvHIV-1 NL4.3 viral genome and contains also a GFP sequence headed by an IRES. The pNL4.3 ∆env ∆NefLuc has the Luciferase cDNA as reporter gene.</p></sec><sec id="s4-4"><title>CRISPR–Cas9 knockout in THP-1 cells</title><p>To target CPSF6, three different crRNAs were used simultaneously (specific sequence: 5′-<named-content content-type="sequence">TCGGGCAAATGGCCAGTCAAAGG</named-content>-3′, 5′-<named-content content-type="sequence">AGGACGGGGCCGTTTTCCAGGGG</named-content>-3′, and 5′-<named-content content-type="sequence">CATGTAATCTCGGTCTTCTGGGG</named-content>-3′, all ordered from Integrated DNA Technologies, IDT). Pre-designed unspecific crRNA was used as control (IDT). crRNA and tracrRNA were resuspended in IDT Duplex Buffer according to the manufacturer’s instructions. On the day of the nucleofection, duplexes were formed by mixing equimolar concentration of crRNA and tracrRNA, followed by 5 min annealing at 95°C. RNA duplexes were then mixed (1:2) with TrueCut Cas9 Protein v2 for 10 min at room temperature to generate ribonucleoprotein (RNP) complexes. 2 × 10<sup>5</sup> THP-1 cells were resuspended in P3 Primary Cell Nucleofector Solution, mixed with RNP and Alt-R Cas9 Electroporation Enhancer (90 pmol, IDT), and nucleofected in a 4D-Nucleofector System using the P3 Primary Cell 4D-NucleofectorX Kit S (program FI-110). After nucleofection, cells were seeded in complete RPMI medium with 20% FBS. Three days after nucleofection, cells were plated for clonal selection.</p></sec><sec id="s4-5"><title>Clonal selection of KO cell lines</title><p>Seventy-two hours post nucleofection, cells were diluted in RPMI medium containing 20% FBS and plated in five 96-well plates at 1 and 5 cells/well condition. After 1 month, selected microcolonies (50–100) are placed into 24-well plates. Once the wells were near confluence, cells were transferred into the well of a 6-well plate. After growing for another 1 month, cells were proceeded for western blot.</p></sec><sec id="s4-6"><title>Western blot</title><p>Proteins were extracted on ice from THP-1 cells using RIPA buffer (20 mM HEPES, pH 7.6, 150 mM NaCl, 1% sodium deoxycholate, 1% Nonidet P-40, 0.1% SDS, 2 mM EDTA, complete protease inhibitor), and protein concentration was quantified using a detergent-compatible (DC) protein assay (Pierce BCA Protein Assay Kit) with bovine serum albumin (BSA) as a standard. 90 µg of total protein lysate were loaded onto SDS–PAGE 4–12% Bis-Tris gels (Invitrogen); an Ab rabbit anti-CPSF6 (1:500) and an anti-rabbit HRP-conjugated (1:5000) were used for the detection of CPSF6, whereas the normalization was done by an Ab anti-actin HRP-conjugated (1:3000). Visualization was carried out using an ECL solution.</p></sec><sec id="s4-7"><title>AUMsilence ASO</title><p>AUMsilenceTM 352 ASOs were synthesized by AUM BioTech, LLC (Philadelphia, USA). THP-1 negative control, THP-1 KD SRRM2, and THP-1 KD SON cells were differentiated with PMA (160 nM) for 48 hr then incubated 72 hr with 10 µM of a AUMsilenceTM ASOs complementary to the mRNA of SRRM2 and SON, respectively (scramble control AUMscrambleTM). All cells were kept in an incubator at 37°C and 5% CO<sub>2</sub>. These cells were cultivated in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin–streptomycin solution (100 U/ml).</p></sec><sec id="s4-8"><title>Cloning</title><p>pSICO CPSF6-mNeonGreen was used to generate deletion mutants by excising different regions from the original sequence according to <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. The mutants were produced with and without the mNeonGreen tag, except for pSICO CPSF6-∆MCD and pSICO CPSF6-∆MCD PY NLS. All primers are specified in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p><p>For pSICO CPSF6-mNeonGreen ∆LCR ADD2, CPSF6 ∆LCR ADD2 sequence was amplified by PCR from pLPCX CPSF6 ADD2 and specific primers were designed to add also BamHI restriction sites at the extremities. Phusion Flash High-Fidelity PCR Master Mix was used and the reaction was performed according to the manufacturer datasheet (100 ng template DNA and 56° annealing temperature). PCR products were treated with DpnI for 1 hr at 37°C and then digested with BamHI restriction enzyme at 37°C for 1 hr. 2 µl of the backbone pSICO CPSF6-mNeonGreen were digested with BamHI at 37°C for 3 hr and further treated with CIP. After gel extraction of the DNA and purification, insert and backbone were ligated with T4 Ligase for 2 hr at 22°C. 5 µl of the product were used to transform 50 µl of DH5α bacteria (30 min at 4°C, 45 s at 42°C, 2 min at 4°C, incubation in SOC medium for 1 hr at 37°C and plating on LB agar dishes).</p><p>All the other mutants were obtained using the <ext-link ext-link-type="uri" xlink:href="https://www.takarabio.com/documents/User%20Manual/In/In-Fusion%20Snap%20Assembly%20User%20Manual.pdf">In-FusionSnap Assembly protocol</ext-link>, which allowed us to amplify the original plasmid, deleting the small region of interest. The different primers used are reported in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. As reported in the <ext-link ext-link-type="uri" xlink:href="https://www.takarabio.com/documents/User%20Manual/In/In-Fusion%20Snap%20Assembly%20User%20Manual.pdf">In-FusionSnap Assembly protocol</ext-link> , 5 ng of the original plasmid were amplified with PrimeSTARMax DNA polymerase in 35 PCR cycles (10 s at 98°C, 15 s at 55°C, 5 s/kb at 72°C). The PCR products were then digested for 1 hr at 37°C using DpnI to get rid of the original plasmid. After plasmid cleaning up, it was circularized through a ligation of 15 min at 50°C. 2.5 µl of products were used in Stellar Competent Cells’ transformation, following the same procedure used for DH5a transformation, previously explained.</p></sec><sec id="s4-9"><title>Lentiviral vectors and viral productions</title><p>LVs and HIV-1 viruses were produced by transient transfection of HEK293T cells through calcium chloride co-precipitation. Co-transfection was performed as follows: for LVs, 10 µg of transfer vector, 10 µg of packaging plasmid (gag-pol-tat-rev), and 2.5 µg of pHCMV-VSV-G envelope plasmid; for VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx viruses and VSV-G/pNL4.3 ∆env ∆Nef IRES GFP-vpx, 10 µg HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) plasmid or pNL4.3 ∆env ∆Nef IRES GFP or pNL4.3 ∆env∆R∆Nef Luc, 2.5 µg of pHCMV-VSV-G plasmid and 3 µg of SIVMAC vpx (<xref ref-type="bibr" rid="bib21">Durand et al., 2013</xref>) or full-length virus 10 µg HIV-1 NL4.3AD8 and 3 µg of SIVMAC vpx. After the collection of the supernatant 48 hr post-transfection, lentiviral particles were concentrated by ultracentrifugation for 1 hr at 22,000 rpm at 4°C and stored at −80°C. LVs and viruses were tittered by qPCR in HEK293T cells 3 days post-transduction.</p></sec><sec id="s4-10"><title>Cell transduction and infection</title><p>THP-1 ctrl CRISPR clone 2 cells and THP-1 (duplex1-2-3 CRISPR) KO clone 4 cells were differentiated with PMA (160 nM) for 72 hr then transduced with different mutants of CPSF6 for 72 hr (MOI = 1) and then infected for 30 hr with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI = 10) in presence of Nevirapine (10 µM). The medium was always supplemented with PMA (160 nM).</p><p>For Halo tagged SRRM2 HEK 293 cells and Halo tagged SRRM2 ∆IDR HEK 293 cells, 2 × 10<sup>5</sup> cells were seeded on coverslips coated with polylysine in complete growth medium (DMEM, GlutaMAX-I, 10% FBS, and 1% P/S) and incubated at 37°C (5% CO<sub>2</sub>) for 24 hr. Cells were then infected with the VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) (MOI 10) in complete growth medium supplemented with Nevirapine (10 mM) for 24 hr.</p><p>THP-1 control (scramble), THP-1 KD SRRM2 cells, and THP-1 KD SON cells were seeded on coverslips and differentiated with PMA (160 nM) for 72 hr. Then incubated for 48 hr with 10 µM of a FANA ASOs (scramble control FANA (SCR-FANA), SRRM<italic>2</italic>-FANA, and <italic>SON</italic>-FANA). ASOs used in this study were designed and synthesized by AUM LifeTech (Philadelphia, PA, USA). Next, cells were infected with the pNL4.3 ∆env ∆Nef IRES GFP-VPX (MOI 25) in complete growth medium and incubated at 37°C in 5% CO<sub>2</sub> for 4 days.</p><p>In the four time points experiment, THP-1 cells were differentiated with PMA (160 nM) for 72 hr. Cells were then infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) -vpx (MOI = 10) in the presence of Nevirapine (10 µM), in complete growth medium supplemented with PMA (160 nM), and incubated at 37°C in 5% CO<sub>2</sub> for 6, 9, 12, 30 hr post-infection.</p></sec><sec id="s4-11"><title>Luciferase assay</title><p>The luciferase assay was performed using Luciferase Assay System (Promega, E4030). Infected differentiated THP-1 cells were washed with PBS and then incubated with Reporter Lysis Buffer at –80 °C overnight. After the thawing, cells were scraped, collected and centrifuged at 12,000 × <italic>g</italic> for 5 min to pull down all the cell debris. The supernatant was collected, and a part was used to react with the luciferase substrate. Data were acquired immediately at the luminometer.</p></sec><sec id="s4-12"><title>THP-1 infection with HIV-1 replication competent virus and viral RNA real-time quantification</title><p>THP-1 cells differentiate into macrophage-like cells within 48 hr under PMA treatment (160 nM). THP-1 cells were cultured at 37°C in 5% CO<sub>2</sub> in RPMI Medium 1640 supplemented with GlutaMAXTM-I, 10% FBS, 1% P/S (100 U/ml), MEM non-essential amino acid solution (0.1 mM), sodium pyruvate (1 mM), and HEPES buffer solution (10 mM). THP-1 cells differentiated into macrophages are infected with HIV-1 NL4.3AD8 with Vpx (MOI 6). Twenty-four hours after infection, the cells were washed and RPMI was added to the cells. Three days post-infection, the supernatant is collected and centrifuged. Total viral RNA was extracted from the supernatant via the QIAamp Viral RNA Mini Kit (QIAGEN, Hilden Germany) following the manufacturer’s protocol. Total viral RNA was eluted into 60 μl of DEPC. vRNA is reverse transcribed into DNA with the Maxima H minus reverse transcriptase (Thermo Scientific, EP0752) following the manufacturer’s protocol and the following primers were used (forward: <named-content content-type="sequence">GCCTCAATAAAGCTTGCCTTGA</named-content>, reverse: <named-content content-type="sequence">TGACTAAAAGGGTCTGAGGGATCT</named-content>). DNA copies for each sample were determined by qPCR and the SYBR green dye. The absolute DNA copies were calculated from a standard curve run in parallel using HIV-1 NL4.3AD8 plasmid. The qPCR cycle was as follows: 15 min at 95°C, 40 cycles (15 s at 95°C, 30 s at 58°C, 30 s at 72°C), 15 s at 95°C, 15 s at 55°C, 20 min melting curve until reaching 95°C, 15 s at 90°C.</p></sec><sec id="s4-13"><title>Immunofluorescence microscopy</title><sec id="s4-13-1"><title>Immunostaining</title><p>On the day of fixation, the cells were washed with PBS and fixed with 4% PFA for 15 min. Cells were treated with glycine 0.15% for 10 min, permeabilized with 0.5% Triton X‐100 for 30 min, and blocked with 1% BSA for 30 min. All antibody incubations were carried out at room temperature in a dark humid chamber, for 1 hr with primary antibodies and for 45 min with secondary antibodies. Washes between antibody incubations and antibody dilutions were done in 1% BSA.</p><p>Primary antibodies were diluted as follows: anti-HA 1:500, anti-CPSF6 1:400, anti-SC35 1:200, anti-SON 1:200, anti-SRRM2 1:200, secondary antibodies used were goat anti-rabbit Alexa-488 1:300 and donkey anti-rabbit Cy3 1:1000 for CPSF6, SON, and SRRM2, goat anti-rat Alexa-647 1:100 for IN-HA, goat anti-mouse Alexa-647 1:300 or goat anti-mouse Alexa-488 1:300 for SC35, donkey anti-mouse Alexa-647 1:300 for SRRM2.</p><p>Finally, cells were stained with Hoechst 33342 1:10,000 for 5 min. Coverslips were mounted on glass slides (Star Frost) with Prolong Diamond Antifade Mountant.</p></sec><sec id="s4-13-2"><title>HaloTag labelling</title><p>To detect the HaloTag in Halo tagged SRRM2 HEK 293 cells and Halo tagged SRRM2 ∆IDR HEK 293 cells, we used HaloTagTMR Ligand following the Technical Manual available at <ext-link ext-link-type="uri" xlink:href="https://www.promega.com/protocols">https://www.promega.com/protocols</ext-link>. Specifically, cells were incubated in DMEM supplemented with HaloTagTMR Ligand (5 µM) for 15 min at 37°C. The ligand-containing medium was then removed and replaced with an equal volume of 1X PBS, repeating the step twice and ending with warm complete medium. Cells were incubated in complete culture medium for 30 min at 37°C. The medium was then removed and replaced with an equal volume of fresh warm culture medium.</p></sec><sec id="s4-13-3"><title>Immuno-RNA FISH</title><p>On the day of fixation, fixed cells were incubated in Permeabilization/Blocking buffer (1% BSA, 0.3% Triton X-100, 2 mM Vanadyl Ribonucleoside complexes (VRCs) in RNase-free PBS) for 1 hr before the antibodies’ incubations. Antibodies were diluted in Permeabilization/Blocking buffer. After the primary and secondary antibody staining (respectively of 1 hr and 45 min) with the respective washes, cells were fixed for a second time in PFA 4% (in RNase-free PBS) for 10 min at room temperature with subsequent washes with RNase-free PBS. In the meantime, 40 pmol of primary smiFISH probes (<xref ref-type="bibr" rid="bib61">Tsanov et al., 2016</xref>) 24 smiFISH probes designed against HIV-1 pol sequence (<xref ref-type="bibr" rid="bib51">Rensen et al., 2021</xref>) were hybridized with 50 pmol of secondary FLAP probe conjugated to a Cy5 fluorophore (Cy5/<named-content content-type="sequence">AATGCATGTCGACGAGGTCCGAGTGTAA</named-content>/Cy5Sp/) in 1X NEBuffer 3 (diluted in RNase-free H<sub>2</sub>O) using a thermocycler. The programme setting follows: 3 min at 85°C, 3 min at 65°C, and 5 min at 25°C. FISH-probe solution was then diluted 1:50 in Hybridization buffer (90% Stellaris RNA-FISH Hybridization Buffer, 10% Deionized Formamide). After the samples were washed in Wash A buffer (20% Stellaris RNA-FISH Wash Buffer A, 10% Deionized Formamide, in RNase-free H<sub>2</sub>O) at room temperature for 5 min, they were placed on parafilm, covered with 50 µl of FISH-probe solution in Hybridization buffer and incubated overnight at 37°C. The next day, cells were washed with Wash A buffer in the dark at 37°C for 30 min. Afterwards, the samples were incubated for 10 min in Hoechst 333342 diluted 1:10,000 in RNase-free H<sub>2</sub>O and then washed with Wash B buffer for 5 min at room temperature in the dark. Finally, the cells were washed in RNase-free H<sub>2</sub>O before the coverslips were mounted on microscopy slides using ProLongTM Diamond Antifade mounting medium. The mounting medium was cured overnight at room temperature under the chemical hood and away from light.</p></sec><sec id="s4-13-4"><title>Image acquisition</title><p>Images were acquired using a Zeiss LSM700 confocal inverted microscope, with a 63× objective (Plan Apochromat, oil immersion, NA = 1.4), using diode lasers at 405, 488, 555, and 639 nm for the respective fluorophores. A pixel size of 0.07 µm was used.</p></sec></sec><sec id="s4-14"><title>Live imaging on HIV-1 infected Halo tagged SRRM2 HEK 293 cells</title><p>Halo tagged SRRM2 HEK293 cells were seeded and transduced with CPSF6-mNeonGreen lentiviral vector (MOI 0.5) for 24 hr. 0.3 × 10<sup>6</sup> cells were then transferred on poly-<sc>l</sc>-lysin coated Ibidi-dishes and infected with VSV-G/HIV-1ΔEnvIN<sub>HA</sub> LAI (BRU) (MOI = 40) in presence of Nevirapine (10 µM) for 2 hr. After having changed the medium and labelled with HaloTagTMR Ligand (5 µM) (see ‘HaloTag labelling’ section) and Hoechst 333342 diluted 1:80000 in complete DMEM medium, 4D movies were acquired.</p><p>3D movies were acquired using a Nikon Ti2-E Confocal Inverted Spinning Disk microscope, using a 63x objective (Plan Apochromat, oil immersion, NA = 1.4) and a sCMOS Hamamatsu camera, Orca Flash 4. Pixel size 6.5 µm, 2048 × 2044 pixel, QE 82%. For the Z stuck, a Z piezo stage was used, with 0.33 µm interval. For live imaging acquisitions, cells were placed in an environmental chamber with 37°C temperature, 5% CO<sub>2</sub> and 21% O<sub>2</sub>.</p></sec><sec id="s4-15"><title>Protein expression and purification</title><p>pET-11a vectors were used to express the HIV-1 capsid protein. Point mutations, A14C and E45C, were introduced using the QuikChange II site-directed mutagenesis kit (Stratagene) according to the manufacturer’s instructions. All proteins were expressed in <italic>E. coli</italic> one-shoot BL21star (DE3) cells (Invitrogen). Briefly, LB medium was inoculated with overnight cultures, which were grown at 30°C until mid log-phase (<italic>A</italic><sub>600</sub>, 0.6–0.8). Protein expression was induced with 1 mM isopropyl-β-d-thiogalactopyranoside overnight at 18°C. Cells were harvested by centrifugation at 5000 × <italic>g</italic> for 10 min at 4°C, and pellets were stored at −80°C until purification. Purification of capsid was carried out as follows. Pellets from 2 l of bacteria were lysed by sonication (Qsonica microtip: 4420; <italic>A</italic> = 45; 2 min; 2 s on; 2 s off for 12 cycles), in 40 ml of lysis buffer (50 mM Tris pH = 8, 50 mM NaCl, 100 mM β-mercaptoethanol and Complete EDTA-free protease inhibitor tablets). Cell debris was removed by centrifugation at 40,000 × <italic>g</italic> for 20 min at 4°C. Proteins from the supernatant were precipitated by incubation with 1/3 of volume of saturated ammonium sulfate containing 100 mM β-mercaptoethanol for 20 min at 4°C and centrifugation at 8000 × <italic>g</italic> for 20 min at 4°C. Precipitated proteins were resuspended in 30 ml of buffer A (25 mM MES pH6.5, 100 mM β-mercaptoethanol) and sonicated two to three times (Qsonica microtip: 4420; <italic>A</italic> = 45; 2 min; 1 s on; 2 s off). The sample was dialysed three times in buffer A (2 hr, overnight, 2 hr). The sample was sonicated and diluted in 500 ml of buffer A and was chromatographed sequentially on a 5-ml HiTrap Q HP column and on a 5-ml HiTrap SP FF column (GE Healthcare), both pre-equilibrated with buffer A. The capsid protein was eluted from HiTrap SP FF column using a linear gradient from 0 to 2 M of NaCl. Absorbance at 280 nm was checked to take the eluted fraction that had higher protein levels. Pooled fractions were dialysed 3 times (2 h, overnight, 2 h) in storage buffer (25 mM MES, 2 M NaCl, 20 mM β-mercaptoethanol). Sample was concentrated using centricons to a concentration of 20 mg/ml and stored at –80 °C.</p></sec><sec id="s4-16"><title>Assembly of stabilized HIV-1 capsid tubes</title><p>1 ml of monomeric capsid (3 or 1 mg/ml) was dialysed in SnakeSkin dialysis tubing 10,000 MWCO (Thermo Scientific) against a buffer that is high in salt and contains a reducing agent (buffer 1: 50 mM Tris, pH 8, 1 M NaCl, 100 mM β-mercaptoethanol) at 4°C for 8 hr. Subsequently, the protein was dialysed against the same buffer without the reducing agent β-mercaptoethanol (buffer 2: 50 mM Tris, pH 8, 1 M NaCl) at 4°C for 8 hr. The absence of β-mercaptoethanol in the second dialysis allows formation of disulphide bonds between cysteine 14 and 43 inter-capsid monomers in the hexamer. Finally, the protein is dialysed against buffer 3 (20 mM Tris, pH 8.0, 40 mM NaCl) at 4°C for 8 hr. Assembled complexes were kept at 4°C up to 1 month.</p></sec><sec id="s4-17"><title>Capsid binding assay protocol</title><p>Human HEK293T cells were transfected for 24 hr with a plasmid expressing the specified CPSF6 variant tagged with mNeonGreen. Cell media was completely removed and cells were lysed in 300 μl of capsid binding buffer (CBB: 10 mM Tris, pH 8.0, 1,5 mM MgCl<sub>2</sub>, 10 mM KCl) by scrapping off the plate. Cells were rotated at 4°C for 15 min and then centrifuged to remove cellular debris (21,000 <italic>× g</italic>, 15 min, 4°C). Cell lysates were incubated with stabilized HIV-1 capsid tubes for 1 hr at 25°C. Subsequently, stabilized HIV-1 capsid tubes were washed by pelleting the complexes by centrifugation at 21,000 × <italic>g</italic> for 2 min. Pellets were washed using resuspension in CBB or PBS. Pellets were resuspended in Laemmli buffer 1X and analysed by western blotting using anti-p24 or anti-mNeonGreen antibodies.</p></sec><sec id="s4-18"><title>Bioinformatics analysis of CPSF6</title><p>Intrinsic disorder propensity of CPSF6 was evaluated using the Rapid Intrinsic Disorder Analysis Online platform (RIDAO) (<ext-link ext-link-type="uri" xlink:href="https://ridao.app/">https://ridao.app/</ext-link>) designed to predict disordered residues and regions in a query protein based on its amino acid sequence (<xref ref-type="bibr" rid="bib12">Dayhoff and Uversky, 2022</xref>). RIDAO yields results by combining the outputs of several commonly used per-residue disorder predictors, such as PONDR VLXT (<xref ref-type="bibr" rid="bib52">Romero et al., 2001</xref>), PONDR VL3 (<xref ref-type="bibr" rid="bib44">Peng et al., 2006</xref>), PONDR VLS2B (<xref ref-type="bibr" rid="bib43">Peng et al., 2005</xref>), PONDR FIT (<xref ref-type="bibr" rid="bib63">Xue et al., 2010</xref>), as well as IUPred2 (Short) and IUPred2 (Long)(<xref ref-type="bibr" rid="bib19">Dosztányi et al., 2005a</xref>; <xref ref-type="bibr" rid="bib20">Dosztányi et al., 2005b</xref>). RIDAO also computes a mean disorder score for each residue based on these. In the resulting intrinsic disorder profile, the disorder score of 0.5 is the threshold between order and disorder, where residues/regions above 0.5 are disordered, and residues/regions below 0.5 are ordered. The disorder score of 0.15 is the threshold between order and flexibility, where residues/regions with the disorder scores above 0.15 but below 0.5 are flexible, and residues/regions below 0.15 are highly ordered.</p><p>Amino acid compositions of the intrinsically disordered C-terminal domain (residues 261–358) of human CPSF6 and its different variants (CPSF6 ΔFG ΔLCR, CPSF6 ΔLCR, CPSF6 ΔFG, and CPSF6 ADD2 ΔLCR) were analysed to evaluate the relative abundance of prion-like low complexity region (LCR) defining uncharged, charged, and Pro residues in these protein regions. The corresponding values of the relative abundance of these residue groups were calculated by dividing numbers of prion-like LCR defining uncharged (Ala, Gly, Val, Phe, Tyr, Leu, Ile, Ser, Thr, Pro, Asn, Gln), charged (Asp, Glu, Lys, Arg), and Pro residues by total number of amino acids in the corresponding protein fragments. As references, we used the corresponding data for protein sequences deposited to the UniProtKB/Swiss-Prot database that provides information on the overall distribution of amino acids in nature (<xref ref-type="bibr" rid="bib3">Bairoch et al., 2005</xref>; PDB Select 25; <xref ref-type="bibr" rid="bib5">Berman et al., 2000</xref>), which is a subset of structures from the Protein Data Bank with less than 25% sequence identity, biased towards the composition of proteins amenable to crystallization studies; and DisProt 3.4 that is comprised of a set of consensus sequences of experimentally determined disordered regions (<xref ref-type="bibr" rid="bib58">Sickmeier et al., 2007</xref>). Per-residue intrinsic disorder propensities of the LCR-FG and ADD2-FG sequences were evaluated by PONDR VLXT (<xref ref-type="bibr" rid="bib52">Romero et al., 2001</xref>), which is sensitive to local peculiarities of the amino acid sequences freely available at <ext-link ext-link-type="uri" xlink:href="http://www.pondr.com/">http://www.pondr.com/</ext-link> (accessed on August 3, 2024). Linear distribution of the net charge per residue within the LCR-FG and ADD2-FG sequences was evaluated by CIDER (<xref ref-type="bibr" rid="bib27">Holehouse et al., 2017</xref>), which is a webserver for the analysis of a wide range of the physicochemical properties encoded by IDP sequences freely available at <ext-link ext-link-type="uri" xlink:href="http://pappulab.wustl.edu/CIDER">http://pappulab.wustl.edu/CIDER</ext-link> (accessed on August 3, 2024). Secondary structure propensities of the LCR-FG and ADD2-FG sequences were evaluated by PSIPRED (<xref ref-type="bibr" rid="bib41">McGuffin et al., 2000</xref>), which is a highly accurate secondary structure prediction method freely available to non-commercial users at <ext-link ext-link-type="uri" xlink:href="http://globin.bio.warwick.ac.uk/psipred/">http://globin.bio.warwick.ac.uk/psipred/</ext-link> (accessed on August 3, 2024).</p></sec><sec id="s4-19"><title>Imaging and statistical analysis</title><p>All images were analysed using Fiji Software. More in detail, for the count of the NSs, a macro was computed to segment cellular nuclei and to select and count the NSs. For the nuclei segmentation, a Gaussian Blur with sigma = 2 was used and for the channel related to the NS, the set threshold was at 7000–46,012 (min and max). For the counting, a ‘size = 10 – Infinity summarize’ was used for the nuclei, whereas for the NSs the size was reduced to ‘size = 0 – Infinity summarize’.</p><p>For live imaging analysis, Arivis software was used to reconstruct the 3D movies.</p><p>All data were statistically analysed with GraphPad Prism 9 (GraphPad Software, La Jolla, California USA, <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">https://www.graphpad.com</ext-link>). Calculations were performed and figures were drawn using Excel 365 or GraphPad Prism 8.0. Statistical analysis was performed, with Wilcoxon matched paired <italic>t</italic>-tests or Mann–Whitney unpaired <italic>t</italic>-tests. Spearman correlation coefficients (<italic>r</italic>) were calculated using GraphPad Prism.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Methodology, Project administration</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Formal analysis</p></fn><fn fn-type="con" id="con10"><p>Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Table (Table 1) describing the deleted regions of CPSF6 protein in different constructs expressing CPSF6 deletion mutants.</title></caption><media xlink:href="elife-103725-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Table (table 2) describing oligonucleotides used for cloning, qPCR, or ASOs.</title></caption><media xlink:href="elife-103725-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-103725-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>From Figure 1 to Figure 8, the source data contain the numerical data used to generate the figures.</p></sec><ack id="ack"><title>Acknowledgements</title><p>FDN is supported by the Institut Pasteur and ANRS grants (ECTZ192036 and ECTZ137593), ANR-PRCI grant, Sidaction grant. CT is supported by fellowships Sidaction, ANR-PRCI. SA is supported by ANRS fellowship ECTZ204694. FD-G, BC, MR, CL, and CB are supported by NIH Grants R01AI087390 and R01AI150455. We gratefully acknowledge the UtechS Photonic BioImaging platform (Imagopole), C2RT at Institut Pasteur. We thank the NIH AIDS Reagents programme for supporting us with precious reagents and Addgene.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ay</surname><given-names>S</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>HIV-Induced CPSF6 Condensates</article-title><source>Journal of Molecular Biology</source><volume>435</volume><elocation-id>168094</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2023.168094</pub-id><pub-id pub-id-type="pmid">37061085</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ay</surname><given-names>S</given-names></name><name><surname>Burlaud-Gaillard</surname><given-names>J</given-names></name><name><surname>Gazi</surname><given-names>A</given-names></name><name><surname>Tatirovsky</surname><given-names>Y</given-names></name><name><surname>Cuche</surname><given-names>C</given-names></name><name><surname>Diana</surname><given-names>J-S</given-names></name><name><surname>Scoca</surname><given-names>V</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Roingeard</surname><given-names>P</given-names></name><name><surname>Mammano</surname><given-names>F</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>In vivo HIV-1 nuclear condensates safeguard against cGAS and license reverse transcription</article-title><source>The EMBO Journal</source><volume>44</volume><fpage>166</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/s44318-024-00316-w</pub-id><pub-id pub-id-type="pmid">39623137</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bairoch</surname><given-names>A</given-names></name><name><surname>Apweiler</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Barker</surname><given-names>WC</given-names></name><name><surname>Boeckmann</surname><given-names>B</given-names></name><name><surname>Ferro</surname><given-names>S</given-names></name><name><surname>Gasteiger</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Magrane</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>MJ</given-names></name><name><surname>Natale</surname><given-names>DA</given-names></name><name><surname>O’Donovan</surname><given-names>C</given-names></name><name><surname>Redaschi</surname><given-names>N</given-names></name><name><surname>Yeh</surname><given-names>L-SL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The universal protein resource (UniProt)</article-title><source>Nucleic Acids Research</source><volume>33</volume><fpage>D154</fpage><lpage>D159</lpage><pub-id pub-id-type="doi">10.1093/nar/gki070</pub-id><pub-id pub-id-type="pmid">15608167</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barré-Sinoussi</surname><given-names>F</given-names></name><name><surname>Chermann</surname><given-names>JC</given-names></name><name><surname>Rey</surname><given-names>F</given-names></name><name><surname>Nugeyre</surname><given-names>MT</given-names></name><name><surname>Chamaret</surname><given-names>S</given-names></name><name><surname>Gruest</surname><given-names>J</given-names></name><name><surname>Dauguet</surname><given-names>C</given-names></name><name><surname>Axler-Blin</surname><given-names>C</given-names></name><name><surname>Vézinet-Brun</surname><given-names>F</given-names></name><name><surname>Rouzioux</surname><given-names>C</given-names></name><name><surname>Rozenbaum</surname><given-names>W</given-names></name><name><surname>Montagnier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)</article-title><source>Science</source><volume>220</volume><fpage>868</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1126/science.6189183</pub-id><pub-id pub-id-type="pmid">6189183</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>HM</given-names></name><name><surname>Westbrook</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Gilliland</surname><given-names>G</given-names></name><name><surname>Bhat</surname><given-names>TN</given-names></name><name><surname>Weissig</surname><given-names>H</given-names></name><name><surname>Shindyalov</surname><given-names>IN</given-names></name><name><surname>Bourne</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The protein data bank</article-title><source>Nucleic Acids Research</source><volume>28</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id><pub-id pub-id-type="pmid">10592235</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Rodriguez</surname><given-names>G</given-names></name><name><surname>Gazi</surname><given-names>A</given-names></name><name><surname>Monel</surname><given-names>B</given-names></name><name><surname>Frabetti</surname><given-names>S</given-names></name><name><surname>Scoca</surname><given-names>V</given-names></name><name><surname>Mueller</surname><given-names>F</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Krijnse-Locker</surname><given-names>J</given-names></name><name><surname>Charneau</surname><given-names>P</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Remodeling of the core leads HIV-1 preintegration complex into the nucleus of human lymphocytes</article-title><source>Journal of Virology</source><volume>94</volume><elocation-id>e00135-20</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00135-20</pub-id><pub-id pub-id-type="pmid">32238582</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Rodriguez</surname><given-names>G</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The viral capsid: a master key to access the host nucleus</article-title><source>Viruses</source><volume>13</volume><elocation-id>1178</elocation-id><pub-id pub-id-type="doi">10.3390/v13061178</pub-id><pub-id pub-id-type="pmid">34203080</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buffone</surname><given-names>C</given-names></name><name><surname>Martinez-Lopez</surname><given-names>A</given-names></name><name><surname>Fricke</surname><given-names>T</given-names></name><name><surname>Opp</surname><given-names>S</given-names></name><name><surname>Severgnini</surname><given-names>M</given-names></name><name><surname>Cifola</surname><given-names>I</given-names></name><name><surname>Petiti</surname><given-names>L</given-names></name><name><surname>Frabetti</surname><given-names>S</given-names></name><name><surname>Skorupka</surname><given-names>K</given-names></name><name><surname>Zadrozny</surname><given-names>KK</given-names></name><name><surname>Ganser-Pornillos</surname><given-names>BK</given-names></name><name><surname>Pornillos</surname><given-names>O</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name><name><surname>Diaz-Griffero</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nup153 unlocks the nuclear pore complex for HIV-1 nuclear translocation in nondividing cells</article-title><source>Journal of Virology</source><volume>92</volume><elocation-id>e00648-18</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00648-18</pub-id><pub-id pub-id-type="pmid">29997211</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burdick</surname><given-names>RC</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>M</given-names></name><name><surname>Rawson</surname><given-names>JMO</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>WS</given-names></name><name><surname>Pathak</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HIV-1 uncoats in the nucleus near sites of integration</article-title><source>PNAS</source><volume>117</volume><fpage>5486</fpage><lpage>5493</lpage><pub-id pub-id-type="doi">10.1073/pnas.1920631117</pub-id><pub-id pub-id-type="pmid">32094182</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N-Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Gane</surname><given-names>PJ</given-names></name><name><surname>Opp</surname><given-names>S</given-names></name><name><surname>Ball</surname><given-names>NJ</given-names></name><name><surname>Nicastro</surname><given-names>G</given-names></name><name><surname>Zufferey</surname><given-names>M</given-names></name><name><surname>Buffone</surname><given-names>C</given-names></name><name><surname>Luban</surname><given-names>J</given-names></name><name><surname>Selwood</surname><given-names>D</given-names></name><name><surname>Diaz-Griffero</surname><given-names>F</given-names></name><name><surname>Taylor</surname><given-names>I</given-names></name><name><surname>Fassati</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HIV-1 capsid is involved in post-nuclear entry steps</article-title><source>Retrovirology</source><volume>13</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/s12977-016-0262-0</pub-id><pub-id pub-id-type="pmid">27107820</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Brinkman</surname><given-names>EK</given-names></name><name><surname>Adam</surname><given-names>SA</given-names></name><name><surname>Goldman</surname><given-names>R</given-names></name><name><surname>van Steensel</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Belmont</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mapping 3D genome organization relative to nuclear compartments using TSA-Seq as a cytological ruler</article-title><source>The Journal of Cell Biology</source><volume>217</volume><fpage>4025</fpage><lpage>4048</lpage><pub-id pub-id-type="doi">10.1083/jcb.201807108</pub-id><pub-id pub-id-type="pmid">30154186</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayhoff</surname><given-names>GW</given-names><suffix>II</suffix></name><name><surname>Uversky</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Rapid prediction and analysis of protein intrinsic disorder</article-title><source>Protein Science</source><volume>31</volume><elocation-id>e4496</elocation-id><pub-id pub-id-type="doi">10.1002/pro.4496</pub-id><pub-id pub-id-type="pmid">36334049</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Chaumont</surname><given-names>F</given-names></name><name><surname>Dallongeville</surname><given-names>S</given-names></name><name><surname>Chenouard</surname><given-names>N</given-names></name><name><surname>Hervé</surname><given-names>N</given-names></name><name><surname>Pop</surname><given-names>S</given-names></name><name><surname>Provoost</surname><given-names>T</given-names></name><name><surname>Meas-Yedid</surname><given-names>V</given-names></name><name><surname>Pankajakshan</surname><given-names>P</given-names></name><name><surname>Lecomte</surname><given-names>T</given-names></name><name><surname>Le Montagner</surname><given-names>Y</given-names></name><name><surname>Lagache</surname><given-names>T</given-names></name><name><surname>Dufour</surname><given-names>A</given-names></name><name><surname>Olivo-Marin</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Icy: an open bioimage informatics platform for extended reproducible research</article-title><source>Nature Methods</source><volume>9</volume><fpage>690</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2075</pub-id><pub-id pub-id-type="pmid">22743774</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dharan</surname><given-names>A</given-names></name><name><surname>Bachmann</surname><given-names>N</given-names></name><name><surname>Talley</surname><given-names>S</given-names></name><name><surname>Zwikelmaier</surname><given-names>V</given-names></name><name><surname>Campbell</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus</article-title><source>Nature Microbiology</source><volume>5</volume><fpage>1088</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0735-8</pub-id><pub-id pub-id-type="pmid">32483230</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>CF</given-names></name><name><surname>Hertel</surname><given-names>S</given-names></name><name><surname>Tuckwell</surname><given-names>AJ</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Al-Izzi</surname><given-names>SC</given-names></name><name><surname>Ariotti</surname><given-names>N</given-names></name><name><surname>Sierecki</surname><given-names>E</given-names></name><name><surname>Gambin</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>RG</given-names></name><name><surname>Towers</surname><given-names>GJ</given-names></name><name><surname>Böcking</surname><given-names>T</given-names></name><name><surname>Jacques</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The HIV capsid mimics karyopherin engagement of FG-nucleoporins</article-title><source>Nature</source><volume>626</volume><fpage>836</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06969-7</pub-id><pub-id pub-id-type="pmid">38267582</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Nunzio</surname><given-names>F</given-names></name><name><surname>Danckaert</surname><given-names>A</given-names></name><name><surname>Fricke</surname><given-names>T</given-names></name><name><surname>Perez</surname><given-names>P</given-names></name><name><surname>Fernandez</surname><given-names>J</given-names></name><name><surname>Perret</surname><given-names>E</given-names></name><name><surname>Roux</surname><given-names>P</given-names></name><name><surname>Shorte</surname><given-names>S</given-names></name><name><surname>Charneau</surname><given-names>P</given-names></name><name><surname>Diaz-Griffero</surname><given-names>F</given-names></name><name><surname>Arhel</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human nucleoporins promote HIV-1 docking at the nuclear pore, nuclear import and integration</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e46037</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046037</pub-id><pub-id pub-id-type="pmid">23049930</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>New insights in the role of nucleoporins: a bridge leading to concerted steps from HIV-1 nuclear entry until integration</article-title><source>Virus Research</source><volume>178</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2013.09.003</pub-id><pub-id pub-id-type="pmid">24051001</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Nunzio</surname><given-names>F</given-names></name><name><surname>Uversky</surname><given-names>VN</given-names></name><name><surname>Mouland</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Biomolecular condensates: insights into early and late steps of the HIV-1 replication cycle</article-title><source>Retrovirology</source><volume>20</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.1186/s12977-023-00619-6</pub-id><pub-id pub-id-type="pmid">37029379</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosztányi</surname><given-names>Z</given-names></name><name><surname>Csizmok</surname><given-names>V</given-names></name><name><surname>Tompa</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005a</year><article-title>IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content</article-title><source>Bioinformatics</source><volume>21</volume><fpage>3433</fpage><lpage>3434</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti541</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosztányi</surname><given-names>Z</given-names></name><name><surname>Csizmók</surname><given-names>V</given-names></name><name><surname>Tompa</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2005">2005b</year><article-title>The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins</article-title><source>Journal of Molecular Biology</source><volume>347</volume><fpage>827</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2005.01.071</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durand</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>XN</given-names></name><name><surname>Turpin</surname><given-names>J</given-names></name><name><surname>Cordeil</surname><given-names>S</given-names></name><name><surname>Nazaret</surname><given-names>N</given-names></name><name><surname>Croze</surname><given-names>S</given-names></name><name><surname>Mahieux</surname><given-names>R</given-names></name><name><surname>Lachuer</surname><given-names>J</given-names></name><name><surname>Legras-Lachuer</surname><given-names>C</given-names></name><name><surname>Cimarelli</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tailored HIV-1 vectors for genetic modification of primary human dendritic cells and monocytes</article-title><source>Journal of Virology</source><volume>87</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1128/JVI.01459-12</pub-id><pub-id pub-id-type="pmid">23077304</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>AC</given-names></name><name><surname>Marin</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Achuthan</surname><given-names>V</given-names></name><name><surname>Prellberg</surname><given-names>MJ</given-names></name><name><surname>Palermino-Rowland</surname><given-names>K</given-names></name><name><surname>Lan</surname><given-names>S</given-names></name><name><surname>Tedbury</surname><given-names>PR</given-names></name><name><surname>Sarafianos</surname><given-names>SG</given-names></name><name><surname>Engelman</surname><given-names>AN</given-names></name><name><surname>Melikyan</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Publisher Correction: HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>6165</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20152-w</pub-id><pub-id pub-id-type="pmid">33244008</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>XD</given-names></name><name><surname>Maniatis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus</article-title><source>Nature</source><volume>343</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/343437a0</pub-id><pub-id pub-id-type="pmid">2137203</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Weiskopf</surname><given-names>EN</given-names></name><name><surname>Akkermans</surname><given-names>O</given-names></name><name><surname>Swanson</surname><given-names>NA</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>TU</given-names></name><name><surname>Görlich</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>HIV-1 capsids enter the FG phase of nuclear pores like a transport receptor</article-title><source>Nature</source><volume>626</volume><fpage>843</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06966-w</pub-id><pub-id pub-id-type="pmid">38267583</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gromova</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Csizmadia</surname><given-names>E</given-names></name><name><surname>Cagle</surname><given-names>C</given-names></name><name><surname>Nastasio</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Bonder</surname><given-names>A</given-names></name><name><surname>Patwardhan</surname><given-names>V</given-names></name><name><surname>Robson</surname><given-names>SC</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Longhi</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Silencing of aryl hydrocarbon receptor repressor restrains Th17 cell immunity in autoimmune hepatitis</article-title><source>Journal of Autoimmunity</source><volume>143</volume><elocation-id>103162</elocation-id><pub-id pub-id-type="doi">10.1016/j.jaut.2023.103162</pub-id><pub-id pub-id-type="pmid">38142533</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greig</surname><given-names>JA</given-names></name><name><surname>Nguyen</surname><given-names>TA</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Holehouse</surname><given-names>AS</given-names></name><name><surname>Posey</surname><given-names>AE</given-names></name><name><surname>Pappu</surname><given-names>RV</given-names></name><name><surname>Jedd</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Arginine-enriched mixed-charge domains provide cohesion for nuclear speckle condensation</article-title><source>Molecular Cell</source><volume>77</volume><fpage>1237</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.01.025</pub-id><pub-id pub-id-type="pmid">32048997</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holehouse</surname><given-names>AS</given-names></name><name><surname>Das</surname><given-names>RK</given-names></name><name><surname>Ahad</surname><given-names>JN</given-names></name><name><surname>Richardson</surname><given-names>MOG</given-names></name><name><surname>Pappu</surname><given-names>RV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CIDER: resources to analyze sequence-ensemble relationships of intrinsically disordered proteins</article-title><source>Biophysical Journal</source><volume>112</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2016.11.3200</pub-id><pub-id pub-id-type="pmid">28076807</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hülsmann</surname><given-names>BB</given-names></name><name><surname>Labokha</surname><given-names>AA</given-names></name><name><surname>Görlich</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The permeability of reconstituted nuclear pores provides direct evidence for the selective phase model</article-title><source>Cell</source><volume>150</volume><fpage>738</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.07.019</pub-id><pub-id pub-id-type="pmid">22901806</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ilik</surname><given-names>İA</given-names></name><name><surname>Malszycki</surname><given-names>M</given-names></name><name><surname>Lübke</surname><given-names>AK</given-names></name><name><surname>Schade</surname><given-names>C</given-names></name><name><surname>Meierhofer</surname><given-names>D</given-names></name><name><surname>Aktaş</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SON and SRRM2 are essential for nuclear speckle formation</article-title><source>eLife</source><volume>9</volume><elocation-id>eLife</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.60579</pub-id><pub-id pub-id-type="pmid">33095160</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Bedwell</surname><given-names>GJ</given-names></name><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Yu</surname><given-names>HJ</given-names></name><name><surname>Arnarson</surname><given-names>B</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Radhakrishnan</surname><given-names>R</given-names></name><name><surname>Douglas</surname><given-names>AW</given-names></name><name><surname>Ingram</surname><given-names>ZM</given-names></name><name><surname>Freniere</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2024">2024</year><source>HIV-1 Usurps Mixed-Charge Domain-Dependent CPSF6 Phase Separation for Higher-Order Capsid Binding, Nuclear Entry and Viral DNA Integration</source><publisher-name>Nucleic Acids Research</publisher-name></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>E</given-names></name><name><surname>Schnatwinkel</surname><given-names>J</given-names></name><name><surname>Paissoni</surname><given-names>C</given-names></name><name><surname>Andersson</surname><given-names>E</given-names></name><name><surname>Herrmann</surname><given-names>C</given-names></name><name><surname>Camilloni</surname><given-names>C</given-names></name><name><surname>Jemth</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Disordered regions flanking the binding interface modulate affinity between CBP and NCOA</article-title><source>Journal of Molecular Biology</source><volume>434</volume><elocation-id>167643</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2022.167643</pub-id><pub-id pub-id-type="pmid">35605677</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Ambrose</surname><given-names>Z</given-names></name><name><surname>Martin</surname><given-names>TD</given-names></name><name><surname>Oztop</surname><given-names>I</given-names></name><name><surname>Mulky</surname><given-names>A</given-names></name><name><surname>Julias</surname><given-names>JG</given-names></name><name><surname>Vandegraaff</surname><given-names>N</given-names></name><name><surname>Baumann</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Yuen</surname><given-names>W</given-names></name><name><surname>Takemura</surname><given-names>T</given-names></name><name><surname>Shelton</surname><given-names>K</given-names></name><name><surname>Taniuchi</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Sodroski</surname><given-names>J</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name><name><surname>Coffin</surname><given-names>JM</given-names></name><name><surname>Hughes</surname><given-names>SH</given-names></name><name><surname>Unutmaz</surname><given-names>D</given-names></name><name><surname>Engelman</surname><given-names>A</given-names></name><name><surname>KewalRamani</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Flexible use of nuclear import pathways by HIV-1</article-title><source>Cell Host &amp; Microbe</source><volume>7</volume><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.02.007</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelek</surname><given-names>M</given-names></name><name><surname>Casartelli</surname><given-names>N</given-names></name><name><surname>Pellin</surname><given-names>D</given-names></name><name><surname>Rizzi</surname><given-names>E</given-names></name><name><surname>Souque</surname><given-names>P</given-names></name><name><surname>Severgnini</surname><given-names>M</given-names></name><name><surname>Di Serio</surname><given-names>C</given-names></name><name><surname>Fricke</surname><given-names>T</given-names></name><name><surname>Diaz-Griffero</surname><given-names>F</given-names></name><name><surname>Zimmer</surname><given-names>C</given-names></name><name><surname>Charneau</surname><given-names>P</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chromatin organization at the nuclear pore favours HIV replication</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6483</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7483</pub-id><pub-id pub-id-type="pmid">25744187</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lester</surname><given-names>E</given-names></name><name><surname>Ooi</surname><given-names>FK</given-names></name><name><surname>Bakkar</surname><given-names>N</given-names></name><name><surname>Ayers</surname><given-names>J</given-names></name><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>Wheeler</surname><given-names>J</given-names></name><name><surname>Bowser</surname><given-names>R</given-names></name><name><surname>Carlson</surname><given-names>GA</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components</article-title><source>Neuron</source><volume>109</volume><fpage>1675</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.03.026</pub-id><pub-id pub-id-type="pmid">33848474</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Burdick</surname><given-names>RC</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Hu</surname><given-names>WS</given-names></name><name><surname>Pathak</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HIV-1 cores retain their integrity until minutes before uncoating in the nucleus</article-title><source>PNAS</source><volume>118</volume><elocation-id>2019467118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2019467118</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>JO</given-names></name><name><surname>Rhee</surname><given-names>MS</given-names></name><name><surname>Tse</surname><given-names>WC</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Somoza</surname><given-names>JR</given-names></name><name><surname>Rowe</surname><given-names>W</given-names></name><name><surname>Begley</surname><given-names>R</given-names></name><name><surname>Chiu</surname><given-names>A</given-names></name><name><surname>Mulato</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>D</given-names></name><name><surname>Singer</surname><given-names>E</given-names></name><name><surname>Tsai</surname><given-names>LK</given-names></name><name><surname>Bam</surname><given-names>RA</given-names></name><name><surname>Chou</surname><given-names>C-H</given-names></name><name><surname>Canales</surname><given-names>E</given-names></name><name><surname>Brizgys</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>JR</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Graupe</surname><given-names>M</given-names></name><name><surname>Morganelli</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Halcomb</surname><given-names>RL</given-names></name><name><surname>Saito</surname><given-names>RD</given-names></name><name><surname>Schroeder</surname><given-names>SD</given-names></name><name><surname>Lazerwith</surname><given-names>SE</given-names></name><name><surname>Bondy</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Hung</surname><given-names>M</given-names></name><name><surname>Novikov</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Villaseñor</surname><given-names>AG</given-names></name><name><surname>Cannizzaro</surname><given-names>CE</given-names></name><name><surname>Hu</surname><given-names>EY</given-names></name><name><surname>Anderson</surname><given-names>RL</given-names></name><name><surname>Appleby</surname><given-names>TC</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Mwangi</surname><given-names>J</given-names></name><name><surname>Liclican</surname><given-names>A</given-names></name><name><surname>Niedziela-Majka</surname><given-names>A</given-names></name><name><surname>Papalia</surname><given-names>GA</given-names></name><name><surname>Wong</surname><given-names>MH</given-names></name><name><surname>Leavitt</surname><given-names>SA</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Koditek</surname><given-names>D</given-names></name><name><surname>Stepan</surname><given-names>GJ</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Pagratis</surname><given-names>N</given-names></name><name><surname>Clancy</surname><given-names>S</given-names></name><name><surname>Ahmadyar</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>TZ</given-names></name><name><surname>Sellers</surname><given-names>S</given-names></name><name><surname>Wolckenhauer</surname><given-names>SA</given-names></name><name><surname>Ling</surname><given-names>J</given-names></name><name><surname>Callebaut</surname><given-names>C</given-names></name><name><surname>Margot</surname><given-names>N</given-names></name><name><surname>Ram</surname><given-names>RR</given-names></name><name><surname>Liu</surname><given-names>Y-P</given-names></name><name><surname>Hyland</surname><given-names>R</given-names></name><name><surname>Sinclair</surname><given-names>GI</given-names></name><name><surname>Ruane</surname><given-names>PJ</given-names></name><name><surname>Crofoot</surname><given-names>GE</given-names></name><name><surname>McDonald</surname><given-names>CK</given-names></name><name><surname>Brainard</surname><given-names>DM</given-names></name><name><surname>Lad</surname><given-names>L</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Sundquist</surname><given-names>WI</given-names></name><name><surname>Sakowicz</surname><given-names>R</given-names></name><name><surname>Chester</surname><given-names>AE</given-names></name><name><surname>Lee</surname><given-names>WE</given-names></name><name><surname>Daar</surname><given-names>ES</given-names></name><name><surname>Yant</surname><given-names>SR</given-names></name><name><surname>Cihlar</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical targeting of HIV capsid protein with a long-acting small molecule</article-title><source>Nature</source><volume>584</volume><fpage>614</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2443-1</pub-id><pub-id pub-id-type="pmid">32612233</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luchsinger</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Mardones</surname><given-names>GA</given-names></name><name><surname>KewalRamani</surname><given-names>VN</given-names></name><name><surname>Diaz-Griffero</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Formation of nuclear CPSF6/CPSF5 biomolecular condensates upon HIV-1 entry into the nucleus is important for productive infection</article-title><source>Scientific Reports</source><volume>13</volume><elocation-id>10974</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-37364-x</pub-id><pub-id pub-id-type="pmid">37414787</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marasca</surname><given-names>F</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Vadalà</surname><given-names>R</given-names></name><name><surname>Polimeni</surname><given-names>B</given-names></name><name><surname>Ranzani</surname><given-names>V</given-names></name><name><surname>Paraboschi</surname><given-names>EM</given-names></name><name><surname>Burattin</surname><given-names>FV</given-names></name><name><surname>Ghilotti</surname><given-names>M</given-names></name><name><surname>Crosti</surname><given-names>M</given-names></name><name><surname>Negri</surname><given-names>ML</given-names></name><name><surname>Campagnoli</surname><given-names>S</given-names></name><name><surname>Notarbartolo</surname><given-names>S</given-names></name><name><surname>Sartore-Bianchi</surname><given-names>A</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Prati</surname><given-names>D</given-names></name><name><surname>Montini</surname><given-names>G</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>Torre</surname><given-names>O</given-names></name><name><surname>Harari</surname><given-names>S</given-names></name><name><surname>Grifantini</surname><given-names>R</given-names></name><name><surname>Soldà</surname><given-names>G</given-names></name><name><surname>Biffo</surname><given-names>S</given-names></name><name><surname>Abrignani</surname><given-names>S</given-names></name><name><surname>Bodega</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion</article-title><source>Nature Genetics</source><volume>54</volume><fpage>180</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00989-7</pub-id><pub-id pub-id-type="pmid">35039641</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matreyek</surname><given-names>KA</given-names></name><name><surname>Yücel</surname><given-names>SS</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Engelman</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity</article-title><source>PLOS Pathogens</source><volume>9</volume><elocation-id>e1003693</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003693</pub-id><pub-id pub-id-type="pmid">24130490</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzeo</surname><given-names>L</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Di Cicco</surname><given-names>E</given-names></name><name><surname>Isma</surname><given-names>J</given-names></name><name><surname>Tavernari</surname><given-names>D</given-names></name><name><surname>Samarkina</surname><given-names>A</given-names></name><name><surname>Ostano</surname><given-names>P</given-names></name><name><surname>Youssef</surname><given-names>MK</given-names></name><name><surname>Simon</surname><given-names>C</given-names></name><name><surname>Dotto</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>ANKRD1 is a mesenchymal-specific driver of cancer-associated fibroblast activation bridging androgen receptor loss to AP-1 activation</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>1038</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-45308-w</pub-id><pub-id pub-id-type="pmid">38310103</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuffin</surname><given-names>LJ</given-names></name><name><surname>Bryson</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The PSIPRED protein structure prediction server</article-title><source>Bioinformatics</source><volume>16</volume><fpage>404</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/16.4.404</pub-id><pub-id pub-id-type="pmid">10869041</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>TG</given-names></name><name><surname>Zila</surname><given-names>V</given-names></name><name><surname>Peters</surname><given-names>K</given-names></name><name><surname>Schifferdecker</surname><given-names>S</given-names></name><name><surname>Stanic</surname><given-names>M</given-names></name><name><surname>Lucic</surname><given-names>B</given-names></name><name><surname>Laketa</surname><given-names>V</given-names></name><name><surname>Lusic</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>B</given-names></name><name><surname>Kräusslich</surname><given-names>H-G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HIV-1 uncoating by release of viral cDNA from capsid-like structures in the nucleus of infected cells</article-title><source>eLife</source><volume>10</volume><elocation-id>e64776</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.64776</pub-id><pub-id pub-id-type="pmid">33904396</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Vucetic</surname><given-names>S</given-names></name><name><surname>Radivojac</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>CJ</given-names></name><name><surname>Dunker</surname><given-names>AK</given-names></name><name><surname>Obradovic</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Optimizing long intrinsic disorder predictors with protein evolutionary information</article-title><source>Journal of Bioinformatics and Computational Biology</source><volume>3</volume><fpage>35</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1142/s0219720005000886</pub-id><pub-id pub-id-type="pmid">15751111</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Radivojac</surname><given-names>P</given-names></name><name><surname>Vucetic</surname><given-names>S</given-names></name><name><surname>Dunker</surname><given-names>AK</given-names></name><name><surname>Obradovic</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Length-dependent prediction of protein intrinsic disorder</article-title><source>BMC Bioinformatics</source><volume>7</volume><elocation-id>208</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-7-208</pub-id><pub-id pub-id-type="pmid">16618368</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Mammano</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Oligomerization within virions and subcellular localization of human immunodeficiency virus type 1 integrase</article-title><source>Journal of Virology</source><volume>73</volume><fpage>5079</fpage><lpage>5088</lpage><pub-id pub-id-type="doi">10.1128/JVI.73.6.5079-5088.1999</pub-id><pub-id pub-id-type="pmid">10233971</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Mammano</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The karyophilic properties of human immunodeficiency virus type 1 integrase are not required for nuclear import of proviral DNA</article-title><source>Journal of Virology</source><volume>74</volume><fpage>7119</fpage><lpage>7126</lpage><pub-id pub-id-type="doi">10.1128/jvi.74.15.7119-7126.2000</pub-id><pub-id pub-id-type="pmid">10888652</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pornillos</surname><given-names>O</given-names></name><name><surname>Ganser-Pornillos</surname><given-names>BK</given-names></name><name><surname>Kelly</surname><given-names>BN</given-names></name><name><surname>Hua</surname><given-names>Y</given-names></name><name><surname>Whitby</surname><given-names>FG</given-names></name><name><surname>Stout</surname><given-names>CD</given-names></name><name><surname>Sundquist</surname><given-names>WI</given-names></name><name><surname>Hill</surname><given-names>CP</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>X-ray structures of the hexameric building block of the HIV capsid</article-title><source>Cell</source><volume>137</volume><fpage>1282</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.04.063</pub-id><pub-id pub-id-type="pmid">19523676</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>AJ</given-names></name><name><surname>Jacques</surname><given-names>DA</given-names></name><name><surname>McEwan</surname><given-names>WA</given-names></name><name><surname>Fletcher</surname><given-names>AJ</given-names></name><name><surname>Essig</surname><given-names>S</given-names></name><name><surname>Chin</surname><given-names>JW</given-names></name><name><surname>Halambage</surname><given-names>UD</given-names></name><name><surname>Aiken</surname><given-names>C</given-names></name><name><surname>James</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly</article-title><source>PLOS Pathogens</source><volume>10</volume><elocation-id>e1004459</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004459</pub-id><pub-id pub-id-type="pmid">25356722</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rai</surname><given-names>AK</given-names></name><name><surname>Chen</surname><given-names>JX</given-names></name><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Pelkmans</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Kinase-controlled phase transition of membraneless organelles in mitosis</article-title><source>Nature</source><volume>559</volume><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0279-8</pub-id><pub-id pub-id-type="pmid">29973724</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasaiyaah</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>CP</given-names></name><name><surname>Fletcher</surname><given-names>AJ</given-names></name><name><surname>Price</surname><given-names>AJ</given-names></name><name><surname>Blondeau</surname><given-names>C</given-names></name><name><surname>Hilditch</surname><given-names>L</given-names></name><name><surname>Jacques</surname><given-names>DA</given-names></name><name><surname>Selwood</surname><given-names>DL</given-names></name><name><surname>James</surname><given-names>LC</given-names></name><name><surname>Noursadeghi</surname><given-names>M</given-names></name><name><surname>Towers</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HIV-1 evades innate immune recognition through specific cofactor recruitment</article-title><source>Nature</source><volume>503</volume><fpage>402</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/nature12769</pub-id><pub-id pub-id-type="pmid">24196705</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rensen</surname><given-names>E</given-names></name><name><surname>Mueller</surname><given-names>F</given-names></name><name><surname>Scoca</surname><given-names>V</given-names></name><name><surname>Parmar</surname><given-names>JJ</given-names></name><name><surname>Souque</surname><given-names>P</given-names></name><name><surname>Zimmer</surname><given-names>C</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clustering and reverse transcription of HIV-1 genomes in nuclear niches of macrophages</article-title><source>The EMBO Journal</source><volume>40</volume><elocation-id>e105247</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2020105247</pub-id><pub-id pub-id-type="pmid">33270250</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Obradovic</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Garner</surname><given-names>EC</given-names></name><name><surname>Brown</surname><given-names>CJ</given-names></name><name><surname>Dunker</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Sequence complexity of disordered protein</article-title><source>Proteins</source><volume>42</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1002/1097-0134(20010101)42:1&lt;38::aid-prot50&gt;3.0.co;2-3</pub-id><pub-id pub-id-type="pmid">11093259</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>JY</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scoca</surname><given-names>V</given-names></name><name><surname>Morin</surname><given-names>R</given-names></name><name><surname>Collard</surname><given-names>M</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>Di Nunzio</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>HIV-induced membraneless organelles orchestrate post-nuclear entry steps</article-title><source>Journal of Molecular Cell Biology</source><volume>14</volume><elocation-id>mjac060</elocation-id><pub-id pub-id-type="doi">10.1093/jmcb/mjac060</pub-id><pub-id pub-id-type="pmid">36314049</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal-Maurer</surname><given-names>S</given-names></name><name><surname>DeJesus</surname><given-names>E</given-names></name><name><surname>Stellbrink</surname><given-names>H-J</given-names></name><name><surname>Castagna</surname><given-names>A</given-names></name><name><surname>Richmond</surname><given-names>GJ</given-names></name><name><surname>Sinclair</surname><given-names>GI</given-names></name><name><surname>Siripassorn</surname><given-names>K</given-names></name><name><surname>Ruane</surname><given-names>PJ</given-names></name><name><surname>Berhe</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Margot</surname><given-names>NA</given-names></name><name><surname>Dvory-Sobol</surname><given-names>H</given-names></name><name><surname>Hyland</surname><given-names>RH</given-names></name><name><surname>Brainard</surname><given-names>DM</given-names></name><name><surname>Rhee</surname><given-names>MS</given-names></name><name><surname>Baeten</surname><given-names>JM</given-names></name><name><surname>Molina</surname><given-names>J-M</given-names></name><collab>CAPELLA Study Investigators</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection</article-title><source>The New England Journal of Medicine</source><volume>386</volume><fpage>1793</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2115542</pub-id><pub-id pub-id-type="pmid">35544387</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selyutina</surname><given-names>A</given-names></name><name><surname>Bulnes-Ramos</surname><given-names>A</given-names></name><name><surname>Diaz-Griffero</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Binding of host factors to stabilized HIV-1 capsid tubes</article-title><source>Virology</source><volume>523</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.07.019</pub-id><pub-id pub-id-type="pmid">30056211</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selyutina</surname><given-names>A</given-names></name><name><surname>Persaud</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>KewalRamani</surname><given-names>V</given-names></name><name><surname>Diaz-Griffero</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nuclear import of the HIV-1 core precedes reverse transcription and uncoating</article-title><source>Cell Reports</source><volume>32</volume><elocation-id>108201</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108201</pub-id><pub-id pub-id-type="pmid">32997983</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sickmeier</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>LeGall</surname><given-names>T</given-names></name><name><surname>Vacic</surname><given-names>V</given-names></name><name><surname>Cortese</surname><given-names>MS</given-names></name><name><surname>Tantos</surname><given-names>A</given-names></name><name><surname>Szabo</surname><given-names>B</given-names></name><name><surname>Tompa</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Uversky</surname><given-names>VN</given-names></name><name><surname>Obradovic</surname><given-names>Z</given-names></name><name><surname>Dunker</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>DisProt: the database of disordered proteins</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>D786</fpage><lpage>D793</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl893</pub-id><pub-id pub-id-type="pmid">17145717</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Craigie</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The road to chromatin - nuclear entry of retroviruses</article-title><source>Nature Reviews. Microbiology</source><volume>5</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1579</pub-id><pub-id pub-id-type="pmid">17304248</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>IA</given-names></name><name><surname>Fassati</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The capsid revolution</article-title><source>Journal of Molecular Cell Biology</source><volume>15</volume><elocation-id>mjad076</elocation-id><pub-id pub-id-type="doi">10.1093/jmcb/mjad076</pub-id><pub-id pub-id-type="pmid">38037430</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsanov</surname><given-names>N</given-names></name><name><surname>Samacoits</surname><given-names>A</given-names></name><name><surname>Chouaib</surname><given-names>R</given-names></name><name><surname>Traboulsi</surname><given-names>A-M</given-names></name><name><surname>Gostan</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Zimmer</surname><given-names>C</given-names></name><name><surname>Zibara</surname><given-names>K</given-names></name><name><surname>Walter</surname><given-names>T</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Mueller</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>smiFISH and FISH-quant - a flexible single RNA detection approach with super-resolution capability</article-title><source>Nucleic Acids Research</source><volume>44</volume><elocation-id>e165</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkw784</pub-id><pub-id pub-id-type="pmid">27599845</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Iqbal</surname><given-names>N</given-names></name><name><surname>Courouble</surname><given-names>VV</given-names></name><name><surname>Francis</surname><given-names>AC</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Hudait</surname><given-names>A</given-names></name><name><surname>Annamalai</surname><given-names>AS</given-names></name><name><surname>Bester</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>S-W</given-names></name><name><surname>Shkriabai</surname><given-names>N</given-names></name><name><surname>Briganti</surname><given-names>L</given-names></name><name><surname>Haney</surname><given-names>R</given-names></name><name><surname>KewalRamani</surname><given-names>VN</given-names></name><name><surname>Voth</surname><given-names>GA</given-names></name><name><surname>Engelman</surname><given-names>AN</given-names></name><name><surname>Melikyan</surname><given-names>GB</given-names></name><name><surname>Griffin</surname><given-names>PR</given-names></name><name><surname>Asturias</surname><given-names>F</given-names></name><name><surname>Kvaratskhelia</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Prion-like low complexity regions enable avid virus-host interactions during HIV-1 infection</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>5879</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33662-6</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>B</given-names></name><name><surname>Dunbrack</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>RW</given-names></name><name><surname>Dunker</surname><given-names>AK</given-names></name><name><surname>Uversky</surname><given-names>VN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PONDR-FIT: a meta-predictor of intrinsically disordered amino acids</article-title><source>Biochimica et Biophysica Acta - Proteins and Proteomics</source><volume>1804</volume><fpage>996</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2010.01.011</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>M</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Capsid is a dominant determinant of retrovirus infectivity in nondividing cells</article-title><source>Journal of Virology</source><volume>78</volume><fpage>5670</fpage><lpage>5678</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.11.5670-5678.2004</pub-id><pub-id pub-id-type="pmid">15140964</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gholamalamdari</surname><given-names>O</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Belmont</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TSA-seq reveals a largely conserved genome organization relative to nuclear speckles with small position changes tightly correlated with gene expression changes</article-title><source>Genome Research</source><volume>31</volume><fpage>251</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1101/gr.266239.120</pub-id><pub-id pub-id-type="pmid">33355299</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>ZY</given-names></name><name><surname>Harischandra</surname><given-names>DS</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Ghaisas</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>JY</given-names></name><name><surname>McMonagle</surname><given-names>TP</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Lacuarta</surname><given-names>KD</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease</article-title><source>Science</source><volume>381</volume><elocation-id>eadd6696</elocation-id><pub-id pub-id-type="doi">10.1126/science.add6696</pub-id><pub-id pub-id-type="pmid">37499037</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zila</surname><given-names>V</given-names></name><name><surname>Margiotta</surname><given-names>E</given-names></name><name><surname>Turoňová</surname><given-names>B</given-names></name><name><surname>Müller</surname><given-names>TG</given-names></name><name><surname>Zimmerli</surname><given-names>CE</given-names></name><name><surname>Mattei</surname><given-names>S</given-names></name><name><surname>Allegretti</surname><given-names>M</given-names></name><name><surname>Börner</surname><given-names>K</given-names></name><name><surname>Rada</surname><given-names>J</given-names></name><name><surname>Müller</surname><given-names>B</given-names></name><name><surname>Lusic</surname><given-names>M</given-names></name><name><surname>Kräusslich</surname><given-names>HG</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cone-shaped HIV-1 capsids are transported through intact nuclear pores</article-title><source>Cell</source><volume>184</volume><fpage>1032</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.025</pub-id><pub-id pub-id-type="pmid">33571428</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom"> DH5α</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">#EC0112</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">BL21(DE3)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#C601003</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">Stellar Competent Cells</td><td align="left" valign="bottom">Takara</td><td align="left" valign="bottom">#636763</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"> HEK293T</td><td align="left" valign="bottom"> ATCC</td><td align="left" valign="bottom">#CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Halo tagged SRRM2 HEK293 cells</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Lester et al., 2021</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Derived from ATCC Cat# CRL-3275, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_DA04">CVCL_DA04</ext-link></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Halo tagged SRRM2 ∆IDR HEK293 cells</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Lester et al., 2021</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Derived from ATCC Cat# CRL-3275, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_DA04">CVCL_DA04</ext-link></td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">THP-1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">#TIB-202</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">THP-1 KO CPSF6</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat monoclonal anti-HA</td><td align="left" valign="bottom"> Roche</td><td align="left" valign="bottom"> #11867423001</td><td align="char" char="." valign="bottom">1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-p24</td><td align="left" valign="bottom">NIH reagent</td><td align="left" valign="bottom">#NIH183-H12-5C</td><td align="char" char="." valign="bottom">1:400</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit monoclonal anti-CPSF6</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">#NBP1-85676</td><td align="left" valign="bottom">IF 1:400<break/>WB 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-SC35</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">#ab11826</td><td align="char" char="." valign="bottom">1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit monoclonal anti-SON (human)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#HPA031755</td><td align="left" valign="bottom">IF 1:200<break/>WB 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit monoclonal anti-SRRM2</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#HPA066181</td><td align="left" valign="bottom">IF 1:200<break/>WB 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey polyclonal anti-mouse Cy3</td><td align="left" valign="bottom">Jackson Lab</td><td align="left" valign="bottom">#715-165-150</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat polyclonal anti-rat Alexa FluorTM 647</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#A21247</td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat polyclonal anti-rat Alexa FluorTM 555</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#A21434</td><td align="char" char="." valign="bottom">1:300</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat polyclonal anti-rabbit Alexa FluorTM 488</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#A32731</td><td align="char" char="." valign="bottom">1:300</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat polyclonal anti-mouse Alexa FluorTM 647</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#A21235</td><td align="char" char="." valign="bottom">1:300</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse monoclonal anti-β actin HRP-conjugated</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">#8226</td><td align="char" char="." valign="bottom">1:3000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse polyclonal anti-rabbit HRP-conjugated</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">sc2357</td><td align="char" char="." valign="bottom">1:5000</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">HIV-1 (BRU) ∆Env IN(HA) (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib45">Petit et al., 1999</xref>; <xref ref-type="bibr" rid="bib46">Petit et al., 2000</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Used to produce single-round virus</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">HIV-1 NL4.3 ΔEnv ΔVpr Luc</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib17">Di Nunzio, 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Used to produce single-round virus</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">HIV-1 NL4.3 AD8</td><td align="left" valign="bottom">NIH-AIDS Reagent Program</td><td align="left" valign="bottom">#11346</td><td align="left" valign="bottom">Used to produce replicative virus</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">SIV<sub>MAC</sub> Vpx (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib21">Durand et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Used in lentiviral production</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCMV-VSV-G (plasmid)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Plasmid #8454</td><td align="left" valign="bottom">Used in lentiviral vectors’ production</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSD-GP-NDK</td><td align="left" valign="bottom">PlasmidFactory</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Used in lentiviral vectors’ production</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSICO CPSF6-mNeonGreen (plasmid)</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Plasmid #167587</td><td align="left" valign="bottom">Used in lentiviral vectors’ production</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLPCX CPSF6 ADD2 (plasmid)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Wei et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pSICO-CPSF6 mutants (plasmids)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref></td><td align="left" valign="bottom">Used in lentiviral vectors’ production</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Primary smiFISH probes against HIV-1 pol (24)</td><td align="left" valign="bottom"> <xref ref-type="bibr" rid="bib54">Scoca et al., 2023</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Cy5 FLAP (RNA FISH secondary probe)</td><td align="left" valign="bottom">Eurofins Genomics</td><td align="left" valign="bottom">Probe</td><td align="left" valign="bottom">AATGCATG<break/>TCGACGAG<break/>GTCCGAGT<break/>GTAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">qPCR and cloning primers</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"> AUMsilenceTM 352 ASOs against SRRM2 and SON</td><td align="left" valign="bottom"> AUM BioTech</td><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Alt-R CRISPR–Cas9 tracrRNA</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom"># 1072532</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Alt-R CRISPR–Cas9 crRNA</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">Materials and methods</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom"> BamHI-HF</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">#R3136S</td><td align="left" valign="bottom">Used for the cloning</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Quick CIP</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">#M0525S</td><td align="left" valign="bottom">Used for the cloning</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Alt-R S.p. Cas9 V3</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">#10007806</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Transcriptase inverse Maxima H Minus (200 U/μl)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">#EP0752</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">T4 Ligase</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">#EL0011</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">In-Fusion Snap Assembly Master Mix</td><td align="left" valign="bottom">Takara</td><td align="left" valign="bottom">#638947</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Luciferase Assay System</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">#E4030</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">P3 Primary Cell 4D-Nucleofector X Kit S</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom"># V4XP-3032</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NucleoSpin Plasmid</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">#740588.50</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NucleoSpin Plasmid</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">#740416.10</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PCR clean-up and gel extraction</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">#740609.50</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QIAamp Viral RNA Mini Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">#52904</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay Kits</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">#23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bovine serum albumin (BSA)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#A9647</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bradford</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">#500-0006</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Calcium chloride solution</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#21115</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cOmplete, EDTA free (tablet)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#11873580001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Deionized Formamide</td><td align="left" valign="bottom">Bio Basic</td><td align="left" valign="bottom">#FB0211</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ECL solution</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">#RPN2232</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ethanol Absolute</td><td align="left" valign="bottom">Fisher BioReagents</td><td align="left" valign="bottom">#BP2818-500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ethylenediamine tetra-acetic acid disodium salt solution (EDTA)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#E7889</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Foetal bovine serum (FBS)</td><td align="left" valign="bottom">Serana</td><td align="left" valign="bottom">#S-FBS-SA-015</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Glycine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">#G8898</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HaloTagTMR Ligand</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">#G8252</td><td align="left" valign="bottom">1:1000 in cell culture medium for live imaging acquisitions</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES-buffered saline, pH 7.0</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">#J62623.AK</td><td align="left" valign="bottom">Used 1:2 for transfection</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES solution</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">#15630</td><td align="left" valign="bottom">Used for cell culture</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hoechst 33342</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#H3570</td><td align="left" valign="bottom">1:10,000 in water for fixed cells<break/>1:80,000 in cell culture medium for live imaging acquisitions</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NEBuffer 3</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">#B7003S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nevirapine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#SML0097</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NuPAGE Bis-Tris Mini Protein Gels, 4–12%</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#NP0322BOX</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Paraformaldehyde 32%</td><td align="left" valign="bottom">Electron Microscopy Sciences</td><td align="left" valign="bottom">#15714</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin–Streptomycin (P/S)</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">#15140</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PF74</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">#SML0835</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phorbol 12-myristate 13-acetate (PMA)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">#P8139</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Poly-L-lysine solution</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">#P4707</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Precision Plus Protein Western C, Standard solution</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">#1610376</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ProLong Diamond Antifade Mountant</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">#P36970</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Reducing Agent 20X</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">#1610792</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RIPA buffer</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#R0278</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RNaseZAP</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#R2020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Running buffer 20X</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#NP0001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sample Buffer 4X</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">#1610791</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Stellaris RNA FISH Hybridization Buffer</td><td align="left" valign="bottom">Biosearch Technologies</td><td align="left" valign="bottom">#SMF-HB1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Stellaris RNA FISH Wash Buffer A</td><td align="left" valign="bottom">Biosearch Technologies</td><td align="left" valign="bottom">#SMF-WA1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Stellaris RNA FISH Wash Buffer B</td><td align="left" valign="bottom">Biosearch Technologies</td><td align="left" valign="bottom">#SMF-WB1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SuperScript III Platinum SYBR Green One-Step qRT-PCR</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#11736059</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Transfer buffer 20X</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#NP0006-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Triton X-100</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">#T8787</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trypsin 0.05%-EDTA (1X)</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">#253000</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TWEEN 20</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">#P1379</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phusion Flash High-Fidelity PCR Master Mix</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">#F-548S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">UltraPure Distilled Water (H<sub>2</sub>O)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">#10977</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Vanadyl Ribonucleoside Complexes (VRC)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">#94742</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ZEISS arivis Scientific Image Analysis</td><td align="left" valign="bottom">ZEISS</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.arivis.com/">https://www.arivis.com/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CIDER</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib27">Holehouse et al., 2017</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://pappulab.wustl.edu/CIDER">http://pappulab.wustl.edu/CIDER</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib53">Schindelin et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.net/software/fiji/">https://imagej.net/software/fiji/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Icy</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib13">de Chaumont et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://icy.bioimageanalysis.org/download/">https://icy.bioimageanalysis.org/download/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PONDR VLXT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib52">Romero et al., 2001</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism9</td><td align="left" valign="bottom">GraphPad Software</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PSIPRED</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib41">McGuffin et al., 2000</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://globin.bio.warwick.ac.uk/psipred/">http://globin.bio.warwick.ac.uk/psipred/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Rapid Intrinsic Disorder 696 Analysis Online platform (RIDAO)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib12">Dayhoff and Uversky, 2022</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://ridao.app/">https://ridao.app/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">BD SYRINGE 60 ml (no needle)</td><td align="left" valign="bottom">Dutscher</td><td align="left" valign="bottom">#309653</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Centrifuge</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Sorvall ST4 Plus</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Confocal microscope</td><td align="left" valign="bottom">Zeiss</td><td align="left" valign="bottom">LSM700 inverted</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Confocal microscope 63x objective</td><td align="left" valign="bottom">Zeiss</td><td align="left" valign="bottom">Objective Plan-Apochromat 63x/1.4 Oil DIC M27</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Corning black 96 Well Solid Polystyrene Microplate</td><td align="left" valign="bottom">Merck</td><td align="left" valign="bottom">#CLS3916</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Enspire 2300</td><td align="left" valign="bottom">Perkin Elmer</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Falcon Cell culture 24-well plate</td><td align="left" valign="bottom">Dutscher</td><td align="left" valign="bottom">#353047</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Glasstic Slide 10 with Grids</td><td align="left" valign="bottom">KOVA</td><td align="left" valign="bottom">#87144E</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">HiTrapTM Q HP column</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">#17115401</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">HiTrapTM SP FF column</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">#17515701</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Ibidi micro dishes 35 mm high</td><td align="left" valign="bottom">Ibidi</td><td align="left" valign="bottom">#81158</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Minisart NML Syringe Filter 0.45 µm</td><td align="left" valign="bottom">Sartorius</td><td align="left" valign="bottom">#16555</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Open-Top Thin wall Polypropylene Conical Tube, 31.5 ml, 25 × 89 mm</td><td align="left" valign="bottom">Beckman Coulter, Inc</td><td align="left" valign="bottom">#358126</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">OPTILUX Petri dish – 100 × 20 mm</td><td align="left" valign="bottom">Dutscher</td><td align="left" valign="bottom">#353003</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Precision cover glasses 12 mm Æ thickness No. 1.5H</td><td align="left" valign="bottom">Marienfeld</td><td align="left" valign="bottom">#0117520</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Refrigerated benchtop centrifuge</td><td align="left" valign="bottom">Eppendorf</td><td align="left" valign="bottom">Centrifuge 5415 R</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Rotor for LE-80K</td><td align="left" valign="bottom">Beckman Coulter, Inc</td><td align="left" valign="bottom">SW32Ti</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Syngene GeneGenius Bio Imaging System Gel Documentation UV Transilluminator</td><td align="left" valign="bottom">Syngene</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Star-Frost slides 76 × 26 mm</td><td align="left" valign="bottom">Dutscher</td><td align="left" valign="bottom">#100204</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Thermocycler</td><td align="left" valign="bottom">Eppendorf</td><td align="left" valign="bottom">Mastercycler nexus</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Thermocycler (qPCR)</td><td align="left" valign="bottom">Eppendorf</td><td align="left" valign="bottom">Mastercycler realplex2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Ultracentrifuge</td><td align="left" valign="bottom">Beckman Coulter, Inc</td><td align="left" valign="bottom">Optima LE-80K</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103725.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Comas-Garcia</surname><given-names>Mauricio</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Universidad Autónoma de San Luis Potosí</institution><country>Mexico</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This is a <bold>valuable</bold> study that presents <bold>convincing</bold> evidence on the genesis of the CPSF6 condensates that form upon HIV-1 infection and the specific molecular determinants involved in their formation, as well as their interactions with SRRM. The study could be strengthened by assessing the relevance of their findings to infection, and in particular, with reverse transcription and gene expression</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103725.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In recent years, our understanding of the nuclear steps of the HIV-1 life cycle has made significant advances. It has emerged that HIV-1 completes reverse transcription in the nucleus and that the host factor CPSF6 forms condensates around the viral capsid. The precise function of these CPSF6 condensates is under investigation, but it is clear that the HIV-1 capsid protein is required for their formation. This study by Tomasini et al. investigates the genesis of the CPSF6 condensates induced by HIV-1 capsid, what other co-factors may be required and their relationship with nuclear speckels (NS). The authors show that disruption of the condensates by the drug PF74, added post-nuclear entry, blocks HIV-1 infection, which supports their functional role. They generated CPSF6 KO THP-1 cell lines, in which they expressed exogenous CPSF6 constructs to map by microscopy and pull down assays the regions critical for the formation of condensates. This approach revealed that the LCR region of CPSF6 is required for capsid binding but not for condensates whereas the FG region is essential for both. Using SON and SRRM2 as markers of NS, the authors show that CPSF6 condensates precede their merging with NS but that depletion of SRRM2, or SRRM2 lacking the IDR domain, delays the genesis of condensates, which are also smaller.</p><p>The study is interesting and well conducted and defines some characteristics of the CPSF6-HIV-1 condensates. Their results on the NS are valuable. The data presented are convincing.</p><p>I have two main concerns.</p><p>Firstly, the functional outcome of the various protein mutants and KOs is not evaluated. Although Figure 1 shows that disruption of the CPSF6 puncta by PF74 impairs HIV-1 infection, it is not clear if HIV-1 infection is at all affected by expression of the mutant CPSF6 forms (and SRRM2 mutants), or KO/KD of the various host factors. The cell lines are available, and so it should be possible to measure HIV-1 infection and reverse transcription. Secondly, the authors have not assessed if the effects observed on the NS impact HIV-1 gene expression, which would be interesting to know given that NS are sites of highly active gene transcription. With the reagents at hand, it should be possible to investigate this too.</p><p>Comments on revisions:</p><p>The revised version of this paper addresses my concerns.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103725.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>HIV-1 infection induces CPSF6 aggregates in the nucleus that contain the viral protein CA. The study of the functions and composition of these nuclear aggregates have raised considerable interest in the field, and they have emerged as sites in which reverse transcription is completed and in the proximity of which viral DNA becomes integrated. In this work, the authors have mutated several regions of the CPSF6 protein to identify the domains important for nuclear aggregation, in addition to the already-known FG-region; they have characterized the kinetics of fusion between CPSF6 aggregates and SC35 nuclear speckles and have determined the role of two nuclear speckle components in this process (SRRM2, SUN2).</p><p>Strengths:</p><p>The work examines systematically the domains of CPSF6 of importance for nuclear aggregate formation in an elegant manner in which these mutants complement an otherwise CPSF6-KO cell line. In addition, this work evidences a novel role for the protein SRRM2 in HIV-induced aggregate formation, overall advancing our comprehension of the components required for their formation and regulation.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103725.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this study, the authors investigate the requirements for the formation of CPSF6 puncta induced by HIV-1 under a high multiplicity of infection conditions. Not surprisingly, they observe that mutation of the Phe-Gly (FG) repeat responsible for CPSF6 binding to the incoming HIV-1 capsid abrogates CPSF6 punctum formation. Perhaps more interestingly, they show that the removal of other domains of CPSF6, including the mixed-charge domain (MCD), does not affect the formation of HIV-1-induced CPSF6 puncta. The authors also present data suggesting that CPSF6 puncta form individual before fusing with nuclear speckles (NSs) and that the fusion of CPSF6 puncta to NSs requires the intrinsically disordered region (IDR) of the NS component SRRM2. While the study presents some interesting findings, there are some technical issues that need to be addressed and the amount of new information is somewhat limited. Also, the authors' finding that deletion of the CPSF6 MCD does not affect the formation of HIV-1-induced CPSF6 puncta contradicts recent findings of Jang et al. (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkae769">https://doi.org/10.1093/nar/gkae769</ext-link>).</p><p>Comments on revisions:</p><p>The authors have generally addressed my comments.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103725.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tomasini</surname><given-names>Chiara</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Cuche</surname><given-names>Celine</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Ay</surname><given-names>Selen</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Collard</surname><given-names>Maxence</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Bin</given-names></name><role specific-use="author">Author</role><aff><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Rashid</surname><given-names>Mohammad</given-names></name><role specific-use="author">Author</role><aff><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bhattacharjee</surname><given-names>Shaoni</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Tello-Rubio</surname><given-names>Bruno</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Buchrieser</surname><given-names>Julian</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib><contrib contrib-type="author"><name><surname>Luchsinger</surname><given-names>Charlotte</given-names></name><role specific-use="author">Author</role><aff><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Bertelli</surname><given-names>Cinzia</given-names></name><role specific-use="author">Author</role><aff><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Uversky</surname><given-names>Vladimir</given-names></name><role specific-use="author">Author</role><aff><institution>University of South Florida</institution><addr-line><named-content content-type="city">Tampa</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Diaz-Griffero</surname><given-names>Felipe</given-names></name><role specific-use="author">Author</role><aff><institution>Albert Einstein College of Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Di Nunzio</surname><given-names>Francesca</given-names></name><role specific-use="author">Author</role><aff><institution>Institut Pasteur</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>In recent years, our understanding of the nuclear steps of the HIV-1 life cycle has made significant advances. It has emerged that HIV-1 completes reverse transcription in the nucleus and that the host factor CPSF6 forms condensates around the viral capsid. The precise function of these CPSF6 condensates is under investigation, but it is clear that the HIV-1 capsid protein is required for their formation. This study by Tomasini et al. investigates the genesis of the CPSF6 condensates induced by HIV-1 capsid, what other co-factors may be required, and their relationship with nuclear speckels (NS). The authors show that disruption of the condensates by the drug PF74, added post-nuclear entry, blocks HIV-1 infection, which supports their functional role. They generated CPSF6 KO THP-1 cell lines, in which they expressed exogenous CPSF6 constructs to map by microscopy and pull down assays of the regions critical for the formation of condensates. This approach revealed that the LCR region of CPSF6 is required for capsid binding but not for condensates whereas the FG region is essential for both. Using SON and SRRM2 as markers of NS, the authors show that CPSF6 condensates precede their merging with NS but that depletion of SRRM2, or SRRM2 lacking the IDR domain, delays the genesis of condensates, which are also smaller.</p><p>The study is interesting and well conducted and defines some characteristics of the CPSF6-HIV-1 condensates. Their results on the NS are valuable. The data presented are convincing.</p><p>I have two main concerns. Firstly, the functional outcome of the various protein mutants and KOs is not evaluated. Although Figure 1 shows that disruption of the CPSF6 puncta by PF74 impairs HIV-1 infection, it is not clear if HIV-1 infection is at all affected by expression of the mutant CPSF6 forms (and SRRM2 mutants) or KO/KD of the various host factors. The cell lines are available, so it should be possible to measure HIV-1 infection and reverse transcription. Secondly, the authors have not assessed if the effects observed on the NS impact HIV-1 gene expression, which would be interesting to know given that NS are sites of highly active gene transcription. With the reagents at hand, it should be possible to investigate this too.</p></disp-quote><p>We thank the reviewer for her/his valuable feedback on our manuscript. We are pleased to see her/his appreciation of our results, and we did our utmost to address the highlighted points to further improve our work.</p><p>To correctly perform the infectivity assay, we generated stable cell clones—a process that required considerable time, particularly during the selection of clones expressing protein levels comparable to wild-type (WT) cells. To accurately measure infectivity, it was essential to use stable clones expressing the most important deletion mutant, ∆FG CPSF6, at levels similar to those of CPSF6 in WT cells (new Fig.5 A-B). Importantly, we assessed the reproducibility of our experiments by freezing and thawing these clones.</p><p>Regarding SRRM2, in THP-1 cells we were only able to achieve a knockdown, which still retains residual SRRM2 protein, albeit at much lower levels. Due to the essential role of SRRM2 in cell survival, obtaining a complete knockout in this cell line is not feasible, making it difficult to draw definitive conclusions from these experiments.</p><p>In contrast, 293T cells carrying the endogenous SRRM2 deletion mutant (ΔIDR) cannot be infected with replication-competent HIV-1, as they lack expression of CD4 and either CCR4 or CCR5. These cells were instead used to monitor the dynamics of CPSF6 puncta assembly within nuclear speckles. However, they are not a suitable model for studying the impact of the depletion of SRRM2 in viral infection.</p><p>Thus, we performed infectivity assays in a more relevant cell line for HIV-1 infection, THP-1 macrophage-like cells, using both a single-round virus and a replication-competent virus. The new results, shown in Figure 5 C-D, indicate that complete depletion of CPSF6 reduces infectivity, as measured by luciferase expression in a single-round infection (KO: ~65%; ΔFG: ~74%; compared to WT: 100% on average). Notably, a more pronounced defect in viral particle production was observed when WT virus was used for infection (KO: ~21%; ΔFG: ~16%; compared to WT: 100% on average). These findings support the referee’s insightful suggestion that the absence of CPSF6 could also impair HIV-1 gene expression.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>HIV-1 infection induces CPSF6 aggregates in the nucleus that contain the viral protein CA. The study of the functions and composition of these nuclear aggregates have raised considerable interest in the field, and they have emerged as sites in which reverse transcription is completed and in the proximity of which viral DNA becomes integrated. In this work, the authors have mutated several regions of the CPSF6 protein to identify the domains important for nuclear aggregation, in addition to the alreadyknown FG region; they have characterized the kinetics of fusion between CPSF6 aggregates and SC35 nuclear speckles and have determined the role of two nuclear speckle components in this process (SRRM2, SUN2).</p><p>Strengths:</p><p>The work examines systematically the domains of CPSF6 of importance for nuclear aggregate formation in an elegant manner in which these mutants complement an otherwise CPSF6-KO cell line. In addition, this work evidences a novel role for the protein SRRM2 in HIV-induced aggregate formation, overall advancing our comprehension of the components required for their formation and regulation.</p><p>Weaknesses:</p><p>Some of the results presented in this manuscript, in particular the kinetics of fusion between CPSF6aggregates and SC35 speckles have been published before (PMID: 32665593; 32997983).</p><p>The observations of the different effects of CPSF6 mutants, as well as SRRM2/SUN2 silencing experiments are not complemented by infection data which would have linked morphological changes in nuclear aggregates to function during viral infection. More importantly, these functional data could have helped stratify otherwise similar morphological appearances in CPSF6 aggregates.</p><p>Overall, the results could be presented in a more concise and ordered manner to help focus the attention of the reader on the most important issues. Most of the figures extend to 3-4 different pages and some information could be clearly either aggregated or moved to supplementary data.</p></disp-quote><p>First, we thank the reviewer for her/his appreciation of our study and to give to us the opportunity to better explain our results and to improve our manuscript. We appreciate the reviewer’s positive feedback on our study, and we will do our best to address her/his concerns. In the meantime, we would like to clarify the focus of our study. Our research does not aim to demonstrate an association between CPSF6 condensates we use the term &quot;condensates&quot; rather than &quot;aggregates,&quot; as aggregates are generally non-dynamic (Alberti &amp; Hyman, 2021; Banani et al., 2017; Scoca et al., JMCB 2022), and our work specifically examines the dynamic behavior of CPSF6 puncta formed during infection and nuclear speckles. The association between CPSF6 puncta and NS has already been established in previous studies, as noted in the manuscript (PMID: 32665593; 32997983). The previous studies (PMID: 32665593; 32997983) showed that CPSF6 puncta colocalize with SC35 upon HIV infection and in the submitted study we study their kinetics.</p><p>About the point highlighted by the reviewer: &quot;Kinetics of fusion between CPSF6-aggregates and SC35 speckles have been published before.&quot;</p><p>Our study differs from prior work PMID 32665593 because we utilize a full-length HIV genome, and we did not follow the integrase (IN) fluorescence in trans and its association with CPSF6 but we specifically assess if CPSF6 clusters form in the nucleus independently of NS factors and next to fuse with them. In the current study we evaluated the dynamics of formation of CPSF6/NS puncta, which it has not been explored before. Given this focus, we believe that our work offers a novel perspective on the molecular interactions that facilitate HIV / CPSF6-NS fusion.</p><p>We calculated that 27% of CPSF6 clusters were independent from NS at 6 h post-infection, compared to only 9% at 30 h. This likely reflects a reduction in individual clusters as more become fused with nuclear speckles over time. At the same time, these data suggest that the fusion process can begin even earlier. Indeed, it has been reported that in macrophages, the peak of viral nuclear import occurs before 6 h post-infection (doi: 10.1038/s41564-020-0735-8).</p><p>In addition, we have incorporated new experiments assessing viral infectivity in the absence of CPSF6, or in CPSF6-knockout cells expressing either a CPSF6 mutant lacking the FG peptide or the WT protein. As shown in our new Figure 5, these results demonstrate that the FG peptide is critical for viral replication in THP-1 cells.</p><p>For better clarity, we would like to specify that our study focuses on the role of SON, a scaffold factor of nuclear speckles, rather than SUN2 (SUN domain-containing protein 2), which is a component of the LINC (Linker of Nucleoskeleton and Cytoskeleton) complex.</p><p>As suggested by the reviewer, we have revised the text and combined figures to improve clarity and facilitate reader comprehension. We appreciate the constructive comment of the reviewer.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public review):</bold></p><p>In this study, the authors investigate the requirements for the formation of CPSF6 puncta induced by HIV-1 under a high multiplicity of infection conditions. Not surprisingly, they observe that mutation of the Phe-Gly (FG) repeat responsible for CPSF6 binding to the incoming HIV-1 capsid abrogates CPSF6 punctum formation. Perhaps more interestingly, they show that the removal of other domains of CPSF6, including the mixed-charge domain (MCD), does not affect the formation of HIV-1-induced CPSF6 puncta. The authors also present data suggesting that CPSF6 puncta form individual before fusing with nuclear speckles (NSs) and that the fusion of CPSF6 puncta to NSs requires the intrinsically disordered region (IDR) of the NS component SRRM2. While the study presents some interesting findings, there are some technical issues that need to be addressed and the amount of new information is somewhat limited. Also, the authors' finding that deletion of the CPSF6 MCD does not affect the formation of HIV-1-induced CPSF6 puncta contradicts recent findings of Jang et al. (doi.org/10.1093/nar/gkae769).</p></disp-quote><p>We thank the reviewer for her/his thoughtful feedback and the opportunity to elaborate on why our findings provide a distinct perspective compared to those of Jang et al. (doi.org/10.1093/nar/gkae769).</p><p>One potential reason for the differences between our findings and those of Jang et al. could be the choice of experimental systems. Jang et al. conducted their study in HEK293T cells with CPSF6 knockouts, as described in Sowd et al., 2016 (doi.org/10.1073/pnas.1524213113). In contrast, our work focused on macrophage-like THP-1 cells, which share closer characteristics with HIV-1’s natural target cells.</p><p>Our approach utilized a complete CPSF6 knockout in THP-1 cells, enabling us to reintroduce untagged versions of CPSF6, such as wild-type and deletion mutants, to avoid potential artifacts from tagging. Jang et al. employed HA-tagged CPSF6 constructs, which may lead to subtle differences in experimental outcomes due to the presence of the tag.</p><p>Finally, our investigation into the IDR of SRRM2 relied on CRISPR-PAINT to generate targeted deletions directly in the endogenous gene (Lester et al., 2021, DOI: 10.1016/j.neuron.2021.03.026). This approach provided a native context for studying SRRM2’s role.</p><p>We will incorporate these clarifications into the discussion section of the revised manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>(1) Figure 2E: The statistical analysis should be extended to the comparison between the &quot;+HIV&quot; samples.</p></disp-quote><p>We showed the statistics between only HIV+ cells now new Fig. 2D.</p><disp-quote content-type="editor-comment"><p>(2) Figure 4A top panel is out of focus.</p></disp-quote><p>We modified the figure now figure 6A.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) Some of the sentences could be rewritten for the sake of simplicity, also taking care to avoid overstatement.</p></disp-quote><p>We modified the sentences as best as we could.</p><disp-quote content-type="editor-comment"><p>(2) For instance: There is no evidence that &quot;viral genomes in nuclear niches may be contributing to the formation of viral reservoirs&quot; (lines 33-35).</p></disp-quote><p>We changed the sentence as follows: “Despite antiretroviral treatment, viral genomes can persist in these nuclear niches and reactivate upon treatment interruption, raising the possibility that they could play a role in the establishment of viral reservoirs.”</p><disp-quote content-type="editor-comment"><p>(3) Line 53: unclear sentence. &quot;The initial stages of the viral life cycle have been understood.....&quot; The authors certainly mean reverse transcription, but as formulated this is not clear. The authors should also bear in mind that reverse transcription starts already in budding/just released virions.</p></disp-quote><p>We clarified the concept as follows: “the initial stages of the viral life cycle, such as the reverse transcription (the conversion of the viral RNA in DNA) and the uncoating (loss of the capsid), have been understood to mainly occur within the host cytoplasm.”</p><disp-quote content-type="editor-comment"><p>(4) Line 124: the results in Figure 1 are not at all explained in the text. PF74 does not act on CPSF6, it acts on CA and this in turn leads to CPS6 puncta disappearance.</p></disp-quote><p>PF74 binds the same hydrophobic pocket of the viral core as CPSF6. However, when viral cores are located within CPSF6 puncta, treatment with a high dose of PF74 leads to a rapid disassembly of these puncta, while viral cores remain detectable up to 2 hours post-treatment (Ay et al., EMBO J. 2024). Here, we simply describe what we observed by confocal microscopy. Said that HIV-Induced CPSF6 Puncta include both CPSF6 proteins and viral cores as we have now specified.</p><disp-quote content-type="editor-comment"><p>(5) Line 130; 'hinges into two key ...' should be 'hinges on'.</p></disp-quote><p>Thanks we modified it.</p><disp-quote content-type="editor-comment"><p>(6) Supplementary Figures are not cited sequentially in the text.</p></disp-quote><p>We have now modified the numbers of the supplementary figures according to their appearance in the text.</p><disp-quote content-type="editor-comment"><p>(7) Line 44: define FG.</p></disp-quote><p>We defined it.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>Specific comments that the authors should address are outlined below.</p><p>(1) As mentioned in the summary above, the authors' findings seem to be in direct contradiction with recent work published by Alan Engelman's lab in NAR. The authors should address the possible reason(s) for this discrepancy.</p></disp-quote><p>We mention the potential reasons for the differences in the results between our study and Engelman’s lab study in the discussion.</p><disp-quote content-type="editor-comment"><p>(2) The major finding here that deletion of the CFSF6 FG repeat prevents the formation of CFSP6 puncta is unsurprising, as the FG repeat is responsible for capsid binding. This has been reported previously and such mutants have been used as controls in other studies.</p></disp-quote><p>Our study demonstrates that the FG domain is the sole region responsible for the formation of CPSF6 puncta, rather than the LCR or MCD domains. The unique role of the FG domain in CPSF6 that promotes the formation of CPSF6 puncta without the help of the other IDRs during viral infection is a finding particularly novel, as it has not yet been reported in the literature.</p><disp-quote content-type="editor-comment"><p>(3) Line 339, the authors state: &quot;incoming viral RNA has been observed to be sequestered in nuclear niches in cells treated with the reversible reverse transcriptase inhibitor, NEV. When macrophage-like cells are infected in the presence of NEV, the incoming viral RNA is held within the nucleus (Rensen et al., 2021; Scoca et al., 2023). This scenario is comparable to what is observed in patients undergoing antiretroviral therapy&quot;. In what way is this comparable to what is observed in individuals on ART? I see no basis for this statement. Sequestration of viral RNA in the nucleus is not the basis for maintaining the viral reservoir in individuals on therapy.</p></disp-quote><p>Thanks, we rephrased the sentence.</p><disp-quote content-type="editor-comment"><p>(4) General comment: analyzing single-cell-derived KO clones is very risky because of random clonal variability between individual cells in the population. If single-cell-derived clones are used, phenotypes could be confirmed with multiple, independent clones.</p></disp-quote><p>We used a clone completely KO for CPSF6 mainly to investigate the role of a specific domain in condensate formation and it will be difficult that clone selection could have introduced artifacts in this context. Other available clones retain residual endogenous protein, which prevents us from accurately assessing CPSF6 cluster formation in the various deletion mutants. A complete CPSF6 knockout is essential for studying puncta formation, as it eliminates potential artifacts arising from protein tags that could alter the phase separation properties of the protein under investigation.</p><disp-quote content-type="editor-comment"><p>(5) Line 214. &quot;It is predicted to form two short α helices and a ß strand, arranged as: α helix - FG - ß strand - α helix&quot;. What is this based on? No citation is provided and no data are shown.</p></disp-quote><p>In fact, the statement &quot;It is predicted to form two short α helices and a ß strand, arranged as: α helix - FG - ß strand - α helix&quot; is based on the data shown in Figure 4E presenting data generated by PSIPRED.</p><disp-quote content-type="editor-comment"><p>(6) Figure 1B. &quot;Luciferase values were normalized by total proteins revealed with the Bradford kit&quot;. What does this mean? I couldn't find anything explaining how the viral inputs were normalized.</p></disp-quote><p>The amount of the virus used is the same for all samples, we used MOI 10 as described in the legend of Figure 1. It is important to normalize the RLU (luciferase assay) with the total amount of proteins to be sure that we are comparing similar number of cells. Obviously, the cells were plated on the same amount on each well, the normalization in our case it is just an additional important control.</p><disp-quote content-type="editor-comment"><p>(7) I can't interpret what is being shown in the movies.</p></disp-quote><p>We updated the movie 1B and rephrased the movie legends and we added a new suppl. Fig.4B.</p><disp-quote content-type="editor-comment"><p>(8) Figure 5B. The differences seen are very small and of questionable significance. The data suggest that by 6 hpi, around 75% of HIV-induced CPSF6 puncta are already fused with NSs.</p></disp-quote><p>We calculated that 27% of CPSF6 clusters were independent from NS at 6 h post-infection, compared to only 9% at 30 h. This likely reflects a reduction in individual clusters as more become fused with nuclear speckles over time. At the same time, these data suggest that the fusion process can begin even earlier. Indeed, it has been reported that in macrophages, the peak of viral nuclear import occurs before 6 h post-infection (doi: 10.1038/s41564-020-0735-8).</p><disp-quote content-type="editor-comment"><p>(9) Figure 6. Immunofluorescence is not a good method for quantifying KD efficiency. The authors should perform western blotting to measure KD efficiency. This is an important point, because the effect sizes are small, quite likely due to incomplete KD.</p></disp-quote><p>We performed WB and quantified the results, which correlated with the IF data and their imaging analysis. These new findings have been incorporated into Figure 8A. Of note, deletion of the IDR of SRRM2 does not affect the number of SON puncta (Fig.8C), but significantly reduces the number of CPSF6 puncta in infected cells compared to those expressing full-length SRRM2 (Fig.8D).</p><disp-quote content-type="editor-comment"><p>(10) There are a variety of issues with the text that should be corrected.</p><p>The authors use &quot;RT&quot; to mean both the enzyme (reverse transcriptase) and the process (reverse transcription). This is incorrect and will confuse the reader. RT refers to the enzyme (noun, not verb).</p><p>The commonly used abbreviation for nevirapine is NVP, not NEV.</p><p>In line 60, it is stated that the capsid contains 250 hexamers. This number is variable, depending on the size and shape of the capsid. By contrast, the capsid has exactly 12 pentamers.</p><p>Line 75. Typo: &quot;nuclear niches containing, such as like&quot;.</p><p>Line 82. Typo: &quot;the mechanism behinds&quot;.</p><p>Line 102. Typo: &quot;we aim to elucidate how these HIV-induced CPSF6 form&quot;.</p><p>Line 107. Type: &quot;CPSF6 is responsible for tracking the viral core&quot; (&quot;trafficking the viral core&quot;?).</p></disp-quote><p>Thanks, we corrected all of them.</p></body></sub-article></article>